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chapter 1 
Introduction 
Head and neck cancer (HNC) is the 6th most common cancer worldwide, with 
500,000 new cases a year. It is increasing in incidence in the UK (1). HNC affects 
several structures and sites in the head and neck, including the oral cavity, larynx, 
pharynx, nose, eye and skin. These sites are intimately involved in the essential 
functions of communication and eating, as well as the senses of smell, taste, vision 
and hearing. 
 
Why is assessment of the QOL of HNC patients important? 
Both HNC and its treatment have significant and often devastating effects on the 
function, appearance, psychological status, socialisation and individual quality of 
life of patients. As a result, patients with HNC have specific needs often beyond 
those of people diagnosed with other cancers (2-4). For example, when speech is 
affected, patients’ ability to express themselves is impaired and can even be 
severely compromised. These effects and needs are ongoing, and manifest mostly 
in the post-treatment phase. For all these reasons, quality of life (QoL) and its 
assessment are of particular importance in head and neck cancer. 
 
For patients with cancer, the outcome of primary importance to the patient is 
survival. However, despite new methods of treatment, survival from HNC has not 
improved greatly over the past 20 years (5). As a result, when deciding on the 
desirability of a recommended treatment for any particular patient, the quality of 
that survival becomes a major consideration (5). Such QoL effects should normally 
be weighed against the chances of survival and the likely QoL outcomes that other 
available treatment options might offer.   
 
Survival statistics are normally based on 5-year data, and a proportion of patients 
live 10 years or more. Therefore, QoL measurement should be long-term, as well 
as prospective, in order to characterise the QoL, residual deficits and late side 
effects of treatment in patients who are cured, and to identify needs that they may 
have as a result of this. 
 
One of the main aims of studying QoL in HNC is to work towards improving the 
outcomes of treatment. This may be achieved by gaining an understanding of the 
baseline state and post-treatment responses and their determinants so that 
interventions to improve outcomes can be devised. 
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Achieving effective QoL assessment in the clinical setting 
To achieve efficient and effective QoL assessment within a clinical setting in HNC, 
two essential ingredients are required. The first is to understand the progression of 
QoL during a HNC patient’s journey from diagnosis, through treatment and into 
long-term, together with the main determinants of QoL over the different phases of 
their treatment, and the association between QoL and survival. Whilst the short-
medium term QoL journey has been well characterised, there has been little 
research in the HNC literature regarding long-term QoL and its impact on survival 
in HNC (6,7). 
 
The second is to understand how best to utilise QoL assessment of HNC patients, 
and how to introduce it into routine clinical practice. It is now well-recognised that 
there are too many reported tools used to measure QoL in HNC. It is also well-
recognised that further research into validating the tools, and identifying the most 
useful instruments from both the patients’ and the clinicians’ points of view is 
necessary (7) in order to facilitate routine quality of life measurement in the clinic. 
 
Overall objectives 
The objectives herein correspond to the two main sections of the thesis, and are: 
1. To understand and quantify the association between time, survival and QoL in 
HNC, particularly in the long-term (Section One) , and  
2. To explore means of improving QoL assessment, especially in a clinical 
setting, by determining the QoL tools most appropriate for use by HNC patients 
and by HNC clinicians (Section Two). 
 
Specific aims 
SECTION ONE [CHAPTERS 2 - 5] 
Chapter 2: To review the current literature on QoL in HNC, and provide levels of 
evidence for the information and recommendations provided, according to the 
SIGN guidelines (8). 
Chapter 3: (a) To report the first 10 year longitudinal study of QoL in HNC, 
describing the change over time of QoL of a group of long-term (10 year) survivors 
of HNC. (b) To study the association between prognostic indicators of quality of life, 
including socio-demographic factors (age, gender, smoking, alcohol), disease–
related or medical factors (disease extent, disease site - mouth, larynx, pharynx- 
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treatment type, etc) and long-term quality of life measures (global QoL, depression, 
physical symptoms) in the aforementioned patient cohort. 
Chapter 4: To study the association of QoL and psychosocial factors with long-
term survival in a multivariate analysis of prognostic indicators of long-term survival 
from head and neck cancer 
Chapter 5: To review the literature examining the association of QoL and 
psychosocial factors with  long-term survival from head and neck cancer 
 
SECTION TWO [CHAPTERS 6, 7 AND 8] 
Chapter 6: To quantify and qualify the practices of clinicians regarding using QoL 
measurement and QoL tools, and impediments to their use, using a cross-sectional 
survey of HNC clinicians in Australia and New Zealand 
Chapter 7: To identify which QoL HNC questionnaires HNC patients find most 
useful in expressing their QoL concerns. 
Chapter 8: Summarise the main findings and conclusions, discuss clinical 
implications and suggest future avenues of research. 
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Key points 
 Patients’ perceptions differ significantly from doctors’. 
 QoL is an integral part of assessment of outcomes in head and neck 
cancer (HNC). 
 QoL measurement should be routine, prospective, and long-term; 
using brief, patient-reported, validated tools, with both general and 
disease specific modules.  
 QoL should be incorporated in to the management pathway of the 
patient to help improve patient care. 
 QoL is the same after chemoradiotherapy or surgery for HNC, despite 
differences in functional deficits. 
 QoL usually decreases immediately after treatment, then gradually 
increases to pre-treatment levels, usually by 12 months.  
 Further research is required. 
 
 
Introduction 
“Just what constitutes ... quality of life for a particular patient and the therapeutic 
pathway to it often is extremely difficult to judge ...” J R Elkington, 1966. 
 
In the latter half of the 20th century quality-of-life (QoL) emerged as an important 
outcome measure of medical treatment, especially for patients with chronic or 
incurable disorders. It is now common practice to include QoL outcomes when 
considering results of treatment, especially in clinical trials where alternative 
treatments are being compared. For patients with cancer, the quantity of survival is 
naturally the outcome of primary importance, but when deciding on the desirability 
of a recommended treatment for any particular patient, the quality of that survival is 
also a major consideration (1). Such QoL will also normally be weighed against the 
chances of survival and the likely QoL outcomes that other available treatment 
options might offer.  
 
QoL has special relevance for head-and-neck cancer (HNC) patients because of 
the particular difficulties that they may encounter with everyday functioning. Whilst 
traditional outcome measures of HNC do not correlate with patient benefit, QoL 
correlates strongly with satisfaction. Moreover, since different treatment modalities 
give comparable survival, QoL after treatment becomes a major factor for deciding 
treatment modality. Formal QoL assessments in treatment of HNC should help to 
determine the balance between an optimal therapeutic effect on patient survival on 
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the one hand, and an acceptable QoL outcome on the other. Furthermore, it is now 
known that patients’ and doctors’ perspectives of the effects of HNC treatment 
differ considerably.  Some patients do not want to trade survival for function. On 
the other hand, doctors consistently overestimate the mutilative effect of treatment 
on the patient, and consistently wrongly prioritise the aims of patients (1). QoL 
measurement helps the physician understand the patient’s perspective and align 
themselves with that. It can also aid in identifying patients and families with 
psychosocial problems or risk factors, such as alcoholism or depression, needing 
active intervention. Finally, there is some evidence from studies of other cancers to 
suggest that optimising QoL may lead to more treatment - compliant patients, 
resulting in an increase in survival (2) [level 2&3]. 
 
Methods 
 
We searched the following databases: MEDLINE, EMBASE, PubMed, Cochrane, 
CINAHL, and AMED, as well as cross checking with national guidelines, reference 
lists, textbooks and personal reference lists. We used the terms “quality of life” with 
“head and neck” or “larynx” “oral” or “pharynx”. The identified abstracts were 
assessed for relevance. Original articles were assessed as to the quality of 
evidence according to guidelines published on Evidence-Based On-Call website 
(www.eboncall.org). 
 
Results 
THE QOL-CONCEPT: DEFINITION AND MEASUREMENT 
GENERAL PERSPECTIVES 
“... We should recognise that the effects of therapeutic strategies and of therapy 
itself on quality of life are not certain until they have been measured.” David Osoba, 
1991. 
 
Most people probably have an intuitive understanding of the meaning of quality-of-
life (QoL), as the term is frequently referred to and used in relation to health in 
general and cancer in particular. However QoL is often not measured and usually 
not specifically defined so that although it is well accepted as a concept, as a 
clinical outcome measure it represents a relatively new scientific paradigm. Social 
science research has led to the conclusion that QoL has four particular operational 
17 
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characteristics that are incontestable: that is, QoL is a self-reported, subjective, 
multidimensional phenomenon that changes over time (see table 1). 
 
These characteristics provide a perspective of QoL and a basis for understanding 
the concept, but as they stand they do not provide a working definition. To conduct 
QoL research, a general, working definition for QoL is needed. It should 
incorporate the philosophy of patient-based measures and provide a basis for 
comparing patients’ general well-being within and between studies. 
 
DEFINITION 
“Quality-of-life measures the difference between present experience and 
expectations and between perceived and actual goals.”  K C Calman, 1987. 
 
The World Health Organisation (WHO) defines Health-related QoL (HRQoL) as: 
‘an individual’s perception of their positioning in  life in the context of the culture 
and value systems in which they live and in relation to their goals, standards and 
concerns. It is a broad ranging concept affected in a complex way by the person’s 
physical health, psychosocial state, level of independence, social relationships, 
and their relationships to salient features of their environment’ (3) 
 
King et al (4) observed in their review of the “state-of-the-knowledge” of QoL in 
cancer patients that the lack of even a consensus definition of QoL may be related 
to the nature of the concept itself. They identified from the literature to 1995 ten 
descriptors or definitions of health-related QoL. A summary statement from these 
offerings is that QoL is a concept relating to the level of one’s well-being and 
satisfaction and encompassing a range of physical and psychological 
characteristics and limitations that describe one’s ability to function and derive 
satisfaction in doing so. In other words, QoL represents one’s personal, subjective 
assessment of general well-being which can be regarded as a composite scale 
involving many contributing domains. 
 
A key process in the personal integration of the various aspects of one’s life is the 
perceived discrepancy between the reality of what one has, and what one wants, 
or expects, or has had (5). The concept embodied in this process has been called 
the "gap" theory and refers to the gap between reality on the one hand and 
expectations and desires on the other. This gap needs to be self-reported, because 
observers (eg doctors) cannot rate it accurately (1,5). Another key factor in the QoL 
construct is the individual’s ability to adopt and employ various coping strategies 
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(6). A patient-rated global QoL measure will necessarily take account of the gaps 
between expectations and reality, the relative importance of those "gaps" to that 
individual, and how they cope with them. 
 
Health-related QoL (HRQoL) has a disease as the focus. From King et al’s review 
(4), it is apparent that QoL in adults is related to, but distinct from, health status. 
Terrel et al (7) refer to an “overall bother” score as a global QoL measure as a 
result of symptoms related to the HNC condition. They also employ a similar scale 
for patients’ assessment of their response to treatment. Cohen et al (8) see HRQoL 
as a compromise which reflects pre-occupation with the disease rather than the 
patients’ experience of illness. Their preferred approach is to focus on ”existential 
well-being” rather than HRQoL, especially in cancer patients, and this is consistent 
with the definition, and the approach to measurement, of QoL that is used here.  
 
CHARACTERISTICS OF QOL 
Social science research has led to the conclusion that QoL has four particular 
operational characteristics that are incontestable: that is, QoL is a self-reported, 
subjective, multidimensional phenomenon that changes over time (see table 1). 
 
FIRST OPERATIONAL CHARACTERISTIC: SELF-ADMINISTERED QUESTIONNAIRE 
 “... The patient’s viewpoint of what constitutes a good quality of life is at least as 
valid as what a researcher or clinician might suggest.” A John MacSweeney and 
Karen T Labuhn, 1990 
 
An important issue in QoL research is the perspective from which it is defined. It is 
recognised that the patients’ own perspective is the preferred source for QoL data. 
(1,9). An observer is effectively an onlooker of another’s life situation and as such 
will have a limited, or at least different, perspective. Clinical observers have a 
perspective that usually relates to the on-going clinical management of the patient. 
As mentioned previously, there is a wealth of evidence now that shows that clinical 
impressions by observers can be misleading and that patients’ priorities differ from 
health care workers’ (1). Some observations may be quite well correlated between 
physicians and patients – such as degree of disfigurement– but the personal (QoL) 
impact of the observed variations cannot be anticipated (10).   
 
Partners and other family members are observers who usually have specific and 
direct concerns about their relative’s disability and deformity but who do not 
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necessarily rate the patient’s perception QoL accurately (11). Family members’ 
concerns are likely to influence assessment of the patient’s QoL, and this 
perspective may determine the quality and amount of support that patient receives 
(11). Society’s view of QoL for HNC patients may very well also approximate a 
family’s initial response. The net result may be a significant impact on the patient’s 
own QoL assessment.  
 
SECOND OPERATIONAL CHARACTERISTIC: SUBJECTIVE, BUT QUANTIFIABLE DATA 
 “... biologic indicators are not adequate proxies for measures of functional status, 
well-being or other quality-of-life concepts or to changes in these variables over 
time.”  John E Ware Jr, 1991. 
 
Of course, objective measures can be used to monitor progress reliably and to 
validate subjective assessments. List et al (12) have produced a reliable 
performance scale which can discriminate among different levels of functioning 
across a broad spectrum of HNC. List et al’s more recent (13) study of laryngeal 
cancer patients shows “virtually no relationship between [post-operative] 
performance outcome and emotional, social, functional or overall QoL.”  They 
found that patients cope “rather effectively with both acute and residual disease 
and treatment effects … to the extent that these residuals do not globally interfere 
with life satisfaction”. Ware (14) also points out that regression models of objective 
measures of function generally explain less than half of the variance in the patients’ 
rating of that function.  
 
Objective measures of functions such as swallowing, speech, shoulder movement 
and muscle strength measures are quantifiable and reliable. However the effect 
that any specific dysfunction may have on a patient will vary according to many 
factors, so that objective measures are not necessarily valid QoL scores. The use 
of objective measures is said to stem from a “beneficence model” of healthcare 
which assumes that health professionals know what promotes or protects the best 
interests of patients. It is more likely in fact that patients are in the better position 
than clinicians to define good and harm as it relates to them. 
 
Clinicians have traditionally regarded subjective measures as unreliable. Despite 
some problems with inconsistency and difficulties with interpretation and 
measurement, guidelines (15) have emerged from research in several different 
fields of oncology. These guidelines are generally accepted and can be applied for 
the study of QoL in HNC (16) (see Table II). It is now understood that subjective 
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ratings of QoL can be both reliable and valid, and that patients should score their 
own QoL, rather than have it assessed for them by an observer. Several QoL 
instruments have been described for use in HNC. Rogers et al (17) and Ringash 
and Bejzak (9) summarise these very well. The most commonly used instruments 
are discussed later in this chapter. 
  
From a practical standpoint researchers and clinicians should try to obtain 
information from as many perspectives as reasonably possible, but the patients’ 
subjective assessment should form the most important data nucleus, while data 
from clinicians (e.g. the disfigurement scale), “significant others” and objective 
measures (e.g. measures of swallowing) will provide useful supplementary 
information.  
 
THIRD OPERATIONAL CHARACTERISTIC: MULTIDIMENSIONAL NATURE 
 “Ultimately, the combination of quality-of-life domains assessed in a given study is 
a function of the patient population under consideration, the nature of the applied 
treatments and the specific research questions at hand.” Neil K Aaronson, 1990. 
 
The general principle that QoL is a multi-dimensional construct, with contributions 
from several different aspects, or "domains", of life has widespread agreement 
among QoL researchers (1). Certainly single-perspective, uni-dimensional, or 
single-instrument evaluations of QoL are now recognized as inadequate. The 
specific domains contributing to global QoL, or general well-being, will vary 
according to clinical and socio-cultural circumstances (6). 
 
There are several advantages associated with the multidimensional approach in 
the measurement of QoL. These have been identified by Aaronson (18) as follows: 
 
- the positive and negative effects of a given treatment can be disentangled; 
- different effects at different stages may be identified, even in the presence of 
a constant global QoL score which would be insensitive to such changes; 
- both anticipated and unexpected effects can be documented by monitoring 
the different components of QoL. 
 
While specific terminology may differ, the essential components of QoL can be 
divided broadly into four domains: physical function, psychological state, social 
interaction, and somatic sensation/symptoms (Table 1).  
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Other domains are also accepted as contributory, but these are not normally 
included in routine QoL assessments. King et al (4) suggest that any 
comprehensive QoL measure should have a spiritual component. Only 1 of 18 
studies in Gotay and Moore’s (6) review of QoL in HNC included a spiritual 
dimension. Cella and Tulsky (19) also cite two other domains - sexuality/intimacy 
and occupational functioning - which have received rather more attention. Fraser 
(20) considers that QoL should incorporate not only physical, psychological and 
social well-being but also economic, occupational and domestic/family domains. 
Others regard the inclusion of the financial component as an “inappropriate and 
possible distorting addition”. Although the financial consequences of an illness are 
clearly important, their effect upon a patient, and the community as a whole, is 
dependent on the structure of community social support programs rather than the 
biology of the disease. Which dimensions should be included in any study would 
depend on the aim of the study and the profile of the population under review. 
Regardless of the number of domain items, the effect on a patient’s QoL will be 
expressed by way of a global measure. 
 
FOURTH OPERATIONAL CHARACTERISTIC: VARIATION OVER TIME 
 “Ideally the data should describe the QoL of patients before, during and after 
treatment, giving a continuous picture of any changes.” PM Fayers and DR Jones, 
1990. 
 
One of the major basic principles of research into QoL of HNC patients (see Table 
2) is to design a longitudinal study. De Graeff et al (21) discuss the difficulties of 
interpretation of data relating to long-term QoL outcomes effects from cross-
sectional studies of HNC, and King et al (4) state unequivocally that “there is no 
substitute for longitudinal assessment in QoL research” as there is an ebb and flow 
in global QoL in cancer patients. It is also well recognised that QoL and health 
status may not be congruent. This apparent paradox – where patients can be 
severely disabled by treatment and recurrent tumour yet exhibit a relatively good 
QoL, while other patients who are free of disease and who have minor treatment-
related symptoms may be very distressed with a poor QoL – is not unusual. 
Therefore longitudinal studies are important so that patients may be used as their 
own internal controls.  
 
The baseline study is essential if future assessments are to be weighed against the 
initial status. The pre-morbid characteristics that a patient brings to the initial 
consultation are clearly very important in relation to later events. The ideal first 
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assessment should probably therefore be after the time of diagnosis but before the 
beginning of treatment (it is interesting to note that non-cancer patients presenting 
for diagnostic biopsy are more distressed pre-diagnosis than patients who turn out 
to have HNC) (22). The critical QoL value is often not any particular score a patient 
provides at a specific time, but rather the change over time.  This can be 
extrapolated to comparisons of groups of patients where the central issue is not 
necessarily whether the overall score is better in one group, but rather whether the 
change in scores observed over time is different in each group. In that way the 
dynamics controlling QoL outcomes for individual patients and groups of patients 
can be adequately understood. 
 
Longitudinal studies of traditional HNC research differ from longitudinal QoL-
outcomes research in that studies that select survival and disease-free curves as 
primary outcomes derive a single data point from each patient entered in the study. 
That data point is only acquired when the patient either dies or fails therapy. Thus a 
patient can be lost for many years and yet all the survival data can be retrieved if 
he appears in the clinic one day for follow-up. QoL data, because of its fluctuating 
nature, is not recoverable once lost. QoL studies require consistent and careful 
follow-up in order to promote meaningful comparisons and to avoid important loss 
of information. Given adequate data relating to each of the contributing domains, 
and sufficient time for follow-up, it is likely that the principle determinants of poor 
QoL in HNC patients will emerge. Only then may one purposefully pursue 
Aaronson’s suggestion (18) that interventions to improve QoL status be introduced. 
 
METHODOLOGICAL ISSUES SURROUNDING QOL-ASSESSMENT 
"choosing an instrument is an exercise in trade offs" Moinpour et al ,1989 
 
In principle, therefore, QoL measurement in cancer patients should use an 
instrument that not only accounts for likely disease- and treatment-related 
symptoms but also incorporates several other domains and an overall (global) QoL 
rating and follows them over time. These principles are central to any QoL enquiry 
and they lead to the major methodological issues that surround QoL assessment.  
 
First, there is no “gold standard” measure against which any overall QoL score can 
be tested (9). This is not unusual in social science. In fact, when one considers the 
central role that coping strategies may play in determining QoL outcomes, it is no 
surprise that there is also no gold standard for coping ability, even though scales 
such as the ‘Locus of Control’ and the ‘Sense of Coherence’ (1) have been 
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developed, and extensively investigated applied in HNC. Nevertheless, the 
absence of a gold standard should not dissuade one from seeking benchmark 
measures against which to compare any proposed new assessment tools. 
 
The second issue relates to the need for both global and component measures. 
The principles regarding the component-versus-global QoL measurement issue 
have been discussed and developed by Cella and Tulsky (19), and Gotay and 
Moore (6) and reviewed more recently by others (23). While a ‘global’ score 
provides a ready means of comparison between treatments and between patient 
groups, it is also rather non-specific and difficult to interpret. Therefore QoL should 
also be assessed at the multidimensional, or component, level so that clinicians 
obtain the kind of information they require for understanding and interpretation. 
Ideally the functional measures most important in determining general well-being 
for any patient or group of patients will be determined thus enabling health-care 
workers to act upon the results. 
 
In order to obtain an overall QoL score, some researchers have summed the 
assigned scores from several different QoL items (9). This approach presupposes 
that the method of scoring each item actually represents the weighting, or 
importance, that patients generally ascribe to that item, and that there is no 
confounding between items. It also assumes that the selected items represent 
virtually all the important factors that contribute significantly to a patient's overall 
QoL. A question on global QoL in which the patient rates his or her own overall 
QoL is more appropriate, as QoL is more than the sum of its parts (9). Each or any 
of the contributing domain items can then be examined for a correlation with the 
global QoL. Fries & Spitz (24) use the term “hierarchy of patient outcome” to 
describe the relationship between global QoL, its contributing domains, and the 
component measures, and emphasise the importance of recording both global and 
component scores. For example, while the EORTC questionnaire produces an 
aggregate score, it also contains a single-item, overall global QoL measure. This 
has recently also been recognised by the University of Washington group who 
developed one of the first head and neck cancer-specific questionnaires , and who 
have now added a global single-item question to their instrument (9). 
 
A third problem for QoL instruments is that a comprehensive enquiry of all the likely 
contributing domains would result in a very arduous, time-consuming and unwieldy 
questionnaire.  A short enquiry is likely to miss important contributory components, 
and indeed there is a functional dependence of reliability on the length of a test that 
serves to emphasise the importance of ensuring that a questionnaire is not too 
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short. The notional ideal length of a questionnaire is probably best described as 
one in which as much relevant information as possible is obtained without tiring or 
alienating the patient or interfering with the efficient delivery of clinical care. This is 
likely to differ for every clinical department and may take some time to determine 
for any specific situation. Hassan and Weymuller (25) regard the ideal QoL head 
and neck cancer questionnaire to be short, concise, easy to understand, minimise 
opportunity for health-worker bias, and be sensitive to changes in health status.  As 
a general principle, one should probably try to gain a little information about as 
many different domains as possible, rather than to obtain a great deal of 
information and data from a small number of domains. 
 
The fourth major methodological issue relates to generic versus diagnosis-specific 
QoL instruments. Generic questionnaires cover a broad range of items in different 
domains, but tend to lack important questions specific to any cancer site or type so 
that sensitivity and responsiveness to important clinical change may be lacking. 
Generic scales assess concepts that are relevant to everyone, but are not specific 
to any age, disease or treatment group. They contribute unique information about 
QoL that is not captured in disease-specific measures. Many, including Gliklich et 
al (23), believe that it is essential to use both generic and disease-specific 
measures and to analyse them together.  In any event, to ensure content validity, 
questionnaires in cancer patients need to be at least to some degree site-specific 
to accommodate the widely varying nature of disease and treatment-related 
symptoms. These requirements should not discourage the clinician-researcher 
unduly: as Neil Aaronson (18) states, “we cannot ... afford to wait for the ‘ideal’ 
measure or the ‘state of the art’ infrastructure. Incremental improvement in the 
quality of our research can be expected only as we develop hands-on experience 
with the methods that are currently available to us.” 
 
It is disappointing to see that, despite a plethora of publications, no consensus has 
yet emerged as to which specific parameters should be measured, or which 
methods should be used in HNC. One generic instrument that has attained 
widespread popularity and use is the SF-36. This has been applied to many 
different diseases as varied as sinusitis, hypertension, arthritis and gastro-intestinal 
disorders. It records data on 6 domains: physical functioning, role functioning, 
social functioning, mental health, health perceptions and bodily pain. This allows 
comparison between very different conditions providing data on health status 
across groups of patients. Although the result is rather non-specific however, 
because of its generic nature, it has been used for QoL assessment in HNC by 
several authors.  
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HISTORICAL DEVELOPMENT OF QOL IN HNC 
“... since no-one has yet reported a cure by radical operation, there must be no 
basis for argument. It cannot increase comfort to add post-operative anemia to 
cancerous cachexia.”  Chevalier Jackson, 1901. 
 
QoL assessment as part of clinical practice in oncology had its beginnings about 50 
years ago. Early QoL studies in HNC patients were narrative and cross-sectional; 
these were followed at first by simple quantitative measures of various parameters 
and later by longitudinal studies of greater complexity. Relatively few HNC studies 
have reported global QoL and only recently have prospective studies and the 
incorporation of QoL assessment in randomised HNC clinical trials emerged. As 
yet no studies have compared QoL measures from widely different socio-cultural 
groups. 
 
Changing Attitudes 
"In deciding the method of treatment we should not, in our eagerness to achieve 
cure, lightly disregard the crippling that may result from our surgical endeavours".  
M.R. Ewing & Hayes Martin, 1952 
 
Although recognition of the importance of the patient's personal life-satisfaction or 
psychological well-being in the management of an illness goes back to 
Hippocrates’ (c460 - 377 BC) time, the traditional focus of medical care has been 
on the treatment and control of disease, on the assumption that patient benefit will 
follow. So it is that in 1886 Jessett spoke of maxillary cancer “... the only hope we 
have of permanently benefiting the patient  suffering from this disease is by free 
and extensive operations, i.e., thoroughly removing the whole of the cancerous 
tissues and getting to healthy structures.”  
 
Open concern from doctors treating HNC for patients’ psychological well-being 
became increasingly evident in the latter half of the 20th century (26). In 1954, 
Ormerod described the standard practice of taking care before laryngectomy to 
explain to a patient what is entailed in the operation, including counselling by a 
speech therapist and interviews with previous patients. In 1983 Natvig confirmed 
the importance of this in his studies (27). Even so, those concerns were not 
universal: indeed, it was common for the diagnosis to be withheld from patients - a 
situation hardly conducive to systematic psycho-social enquiry. On occasions, 
psychological enquiry of cancer patients was even vigorously opposed (26).  
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Concern for the psycho-social aspects of patients facing death gathered 
momentum in the 1960s with the emergence of the Hospice movement pioneered 
by Cecily Saunders in Britain and Elizabeth Kubler-Ross in the U.S.A.. This 
phenomenon gave considerable impetus to the development of QoL assessment in 
oncology in general. Despite the interest in QoL outcomes after curative therapy, 
the study of effectiveness of palliation for patients with end-stage recurrent disease 
is likely to be one of the most important and useful applications of QoL research in 
head-and-neck cancer. 
 
Terminology 
“‘What kind of a device would you call this?’ asked one of his scientific friends 
present. ‘I call it an X ray,’ said Roentgen.” Donald T Atkinson, 1958 
 
The term "Quality-of-life", was first used in an essay submitted to the Dwight 
Eisenhower’s Presidential Commission on National Goals by A.L. Heckscher (26). 
In 1977 "quality-of-life" became a 'key word' by which journal articles could be 
retrieved by the United States National Library of Medicine Medline Computer 
Search program. Since then, there has been a steadily increasing body of QoL-
related clinical research, including work related to HNC, as evidenced in recent 
reviews. 
 
QoL Measurements and Measurers 
“Opinions vary as to the usefulness and interpretation of various quality of life 
instruments (but) the need to consider the possible impact of treatment on QoL is 
widely recognized”  Trotti, et al, 1998. 
 
The history of QoL measurement follows the history of the development of the QoL 
concept, and the evolution of the science of psychometric analysis. Quantitative 
assessment of QoL in cancer patients had its beginnings in the latter half of the 
1940s (26), although the psycho-social impact of treatment was regarded at that 
time as not generally quantifiable. 
 
Before 1980 the validity and range of QoL measurement devices was such that few 
useful studies emerged. The patient interviews that formed the basis of many 
reports were usually not defined, and those psychometric instruments that were 
described were directed at only one or two QoL aspects, such as emotional state. 
Only very limited information could be derived with these study designs.  
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In 1981, McNeil et al (28) provided some insight to society’s values in their analysis 
of the trade-offs that different groups within the community were prepared to 
consider in respect of treatment alternatives for advanced laryngeal cancer. They 
concluded that (healthy) people were prepared to trade 2 or 3 years of life in return 
for preservation of the larynx when considering treatment options for a theoretical 
advanced laryngeal cancer. 
 
In the 1980s, it became possible to test the psychometric properties of QoL 
instruments. Several cross-sectional studies developed and tested the reliability 
and validity of modern QoL instruments devised using Guyatt’s principles (9). The 
most comprehensive cross-sectional study of HNC patients from the early studies 
was reported by Natvig (27). The research was confined to patients in Norway who 
had had a total laryngectomy between 6 months and 18 years previously, and 
represented a valiant effort to cover all aspects of the impact of the surgery, 
including physical, social, psychological and occupational aspects of life. In 
general, the early cross-sectional studies were concerned with laryngeal cancer 
and laryngectomy. Those reports relating to oral and pharyngeal cancers indicated 
that rehabilitative concerns were often greater than those generally encountered 
after laryngectomy. 
 
Social scientists (e.g. Gotay and Moore [6]) see that HNC is ideally suited to QoL 
measurement and that “the development and application of vigorous scientific 
research in this field holds enormous promise”. Although the potential importance 
of QoL outcomes in HNC research is probably still not fully appreciated by many 
clinical otolaryngologists, there is considerable interest in the QoL paradigm from 
both disciplines. In 1983, a paper from Sweden was the first collaborative effort 
between an otolaryngologist and a social scientist, and the first to provide a 
quantified QoL index in head-and-neck cancer. Since then there have been many 
examples. 
 
The most recent step in the evolution of QoL measurement has been the 
longitudinal studies - where patients act as their own ‘controls’ - and data from 
clinical trials where like groups can be legitimately compared. These provide a 
much more reliable basis upon which to reliably determine those factors which 
influence QoL outcomes. 
 
Pruyn et al (11) searched the literature for studies of psychosocial aspects of HNC 
and found 117 studies to 1984, of which only 13 “chose a longitudinal approach”. 
Most of those studies were limited in scope – such as voice rehabilitation following 
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total laryngectomy – and were not very sophisticated from a psychometric 
perspective. Pruyn’s group have produced a further, similar review for the period 
1984 to 1995 (29). There was a clear increase in the proportion of prospective 
studies (16 out of 50 selected studies). Several of the longitudinal studies used 
instruments with good psychometric properties and somewhat broader parameters 
than earlier reports. Most of the studies were of rather limited duration (3-6 months) 
although studies of 2 and 3 years’ duration are now appearing. Longitudinal studies 
of less than 12 months’ duration have probably been too short to draw conclusions 
regarding overall QoL outcomes after treatment for HNC.  
 
Nowadays it is standard practice to include QoL considerations in clinical research, 
to the extent that QoL has become a recommended end-point in clinical trials, and 
the National Cancer Institute of Canada Clinical trials Group now incorporate QoL 
data in all their clinical trials. 
 
CURRENT QOL INSTRUMENTS FOR HNC 
“It is hard properly to evaluate human suffering: the blind say they would rather be 
blind than deaf; whilst the patient without a voice considers himself fortunate that 
he is neither blind nor deaf.”  Leroy A Schall, 1954. 
 
Guidelines for development of QoL questionnaires 
‘researchers should undertake comprehensive literature searches to ascertain 
whether a suitable measure is available before they decide to develop a new 
[measure]’ Garratt et al, 2002. 
 
The science of psychometric and clinimetric measures has developed to the stage 
where a considerable degree of confidence in reliability and validity can be 
generated in the data from self-administered questionnaires. Kirshner and Guyatt 
(15) have developed a framework for evaluating health indices such as QoL 
assessment, in which they describe the basic steps for the development of an 
instrument (Table 2). Kirschner & Guyatt’s (15) requirements for development of 
QoL questionnaire items are: selection of item pool, item scaling, item reduction, 
reliability, validity, and responsiveness. The issue of questionnaire validity is a 
notion that is not traditionally familiar to clinicians. Bombardier and Tugwell (30) 
provide guidelines for assessing questionnaire validity, in terms that can be readily 
understood by medical readers (Table 3).  
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The principles embodied in those steps have been incorporated and developed 
into a guideline for the study of QoL by the European Organisation for Research 
and Treatment of Cancer (EORTC) (16). The EORTC QoLQ-30 core questionnaire 
has been through this development process (16). It represents a generic QoL 
instrument and, to it has been added an ‘Head and Neck’ site-specific module 
designed for HNC patients. An instrument subjected to this kind of rigor will be 
robust and able to provide meaningful data for analysis.  
 
Summary of commonly used QoL instruments 
“Choosing which instrument to use poses a challenge for investigators of QoL in 
head and neck cancer. No one instrument is ideal for all purposes.” Ringash and 
Bezjak, 2001 
 
There are now many instruments in use for assessing QoL in cancer patients and 
several (71 were identified in a recent review [9]) have been developed or adapted 
specifically for head and neck cancer. Many studies have conducted cross-
validation of HNC-specific instruments with various generic instruments, and 
between HNC-specific questionnaires, so that the validity and reliability of many 
instruments has now been determined (6,9). The most commonly used measures 
of QoL have been summarised in Tables 4 and 5. The information presented has 
been adapted mainly from the excellent structured review of commonly used QoL 
instruments in head and neck cancer by Ringash and Bezjak (2001) (9).  
 
All the instruments included have their particular strengths and weaknesses, and it 
is acknowledged that no one measure exists for all purposes. The informed 
selection of a measure appropriate for a specific requirement is essential, and may 
be guided by structured reviews, consensus and expert opinion. To take the 
situational examples mentioned by Ringash and Bezjak in their review (9), the 
EORTC or FACT may be useful for studies comparing HNC patients to those with 
other cancers, as these tools have general as well as specific modules, and have 
been used extensively to assess different cancers. If, on the other hand, the aim 
was to study very specific patient groups, then a very specific tool eg HNRQ for 
radiotherapy patients and UoWQoL of surgical patients, may be more sensitive. 
For international or multi-cultural studies, the EORTC or FACT may be most 
appropriate as they have been translated into several languages, and the EORTC 
has been assessed cross-culturally. 
 
Garratt et al (31) suggest that “researchers should undertake comprehensive 
literature searches to ascertain whether a suitable measure is available before they 
30 
Background: quality of life in head and neck cancer  
decide to develop a new (measure)”. Aaronson (26) advocates that energy be 
spent searching for existing instruments to suit (perhaps with some modification) 
rather than expended on generating new instruments. This is a view supported by 
many. Future efforts should be directed at completing the assessment of reliability, 
responsiveness and validity of current measures, concentrating on direct 
comparisons between measures, and on determining the most appropriate tools for 
particular situations. [Grade B]. 
 
WHAT DO WE KNOW ABOUT QOL IN HNC? 
There are many apparent inconsistencies in QoL research in HNC patients that are 
probably related to many different factors, such as patient case-mix, local 
treatment, and method of voice rehabilitation after laryngectomy (oesophageal 
voice versus tracheo-oesophageal puncture), available social support, and cultural 
and ethnic issues. Measuring QoL outcomes using clinical trial methodology can 
control some of these factors. 
 
 
Impact of Time on QoL 
"there was a significant improvement between diagnosis and the 3 year 
assessment for global QoL"  Hammerlid et al, 2001. 
 
The longitudinal studies of QoL in HNC reported to date have generally used 
different instruments to measure QoL. In those studies where different instruments 
are compared, it has been shown consistently that the different QoL measures 
correlate strongly with each other, which suggests that the different questionnaires 
are measuring the same phenomenon, but in slightly different ways.  
 
In general, studies show that QoL at diagnosis is lower for HNC patients than for 
the population in general (32). This worsens during and immediately after 
treatment. In Hammerlid et al’s study (33), QoL reached its worst level one month 
after radiotherapy treatment, and three months after total laryngectomy. Schliepake 
et al (2002) found the same was true for reconstructed oral cancer resections (34). 
QoL then starts improving, so that by one year after treatment QoL returns to pre-
treatment levels (32,35). There appears to be slight further improvement between 
the first and third years, as reported by Hammerlid et al (35).  Morton (5) showed 
no significant drop in general well-being (global QoL) at 3 months after treatment, 
but a significant improvement, compared with pre-treatment levels, after 12 and 24 
months. By three years, although patients still suffer significant functional deficits, 
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their global QoL shows no significant differences to the general population. (35) 
[Level 2] 
 
 
Impact of Site and Stage of Disease on QoL 
“Patients with large tumours were more affected by their disease than patients with 
small tumours" Hammerlid et al, 1998. 
 
QoL is positively correlated with the stage and site of the disease (36, 38). The 
effect of stage of the primary tumour on QoL may seem as a surrogate for the 
effects of treatment, as one determines the other. However, even at diagnosis, 
stage III and IV laryngeal tumours have lower global QoL scores than stage I and II 
(33). Furthermore, QoL improved after treatment for all stages, but still remained 
lower for the more advanced tumours. De Graeff et al found that the same was true 
for oral cancers (36), and Rogers et al found that tumour size for oral cancer was a 
significant predictor of post-treatment QoL at 1 year (37). Therefore it would appear 
that the stage of the disease independently affects QoL. Interestingly, Hammerlid 
et al found that the difference in QoL due to stage appears to increase with time 
after treatment, so that it was greater at three years than at diagnosis (35). [level 2] 
 
The site of the primary tumour not only affects functions specific to that site, but 
also appear to affect global QoL. Weymuller et al in their prospective study of 210 
patients found that hypopharyngeal tumours have the worst global scores and 
laryngeal tumour patients have the best (38). Other studies have found the same. 
Moreover, within one site, subsites differ in their effect on QoL, eg tongue base 
tumours have the worst QoL amongst oral cancers (37). [level 2&3]. 
 
 
Impact of Treatment on QoL 
"Results suggest that total laryngectomy is not necessarily a disastrous event for 
most patients" Morton, 1997. 
 
Many HNC patients do not want to trade off survival for function (39). Therefore, 
survival is the consideration that should be of primary importance whenever cancer 
treatments are compared and the QoL aspects of care need to be reviewed in the 
light of the eventual survivorship.  
 
There appears to be a perception amongst some clinicians that because 
radiotherapy does not result in tissue loss, it must lead to a better QoL. This is not 
32 
Background: quality of life in head and neck cancer  
supported by data. It is important when counselling patients and deciding on 
treatment options to bear in mind that any treatment modality in HNC, whether it be 
surgery, radiotherapy or a combination of both, results in significant morbidity and a 
negative impact on QoL. 
 
It is also important to remember that current evidence suggests that QoL is 
primarily not determined by treatment modality. Furthermore, functional limitations 
caused by treatment do not necessarily translate into worse QoL. In other words, 
QoL does not correlate with physiologic measures of function. List et al (13) found 
no difference in global QoL between total laryngectomy, hemi-laryngectomy and 
radiotherapy treatment groups in their study of 21 laryngeal cancer patients. They 
however demonstrated quite marked differences between these treatment groups 
in respect of symptoms and physical functioning scores related to speech and 
deglutition. They stated that their findings “contradicted expectations that functional 
restrictions … would have a negative impact on overall QoL”.  
 
Another report, by Morton (39), comparing QoL outcomes of laryngeal cancer 
patients treated either by radiotherapy or total laryngectomy showed similar 
apparently counter-intuitive results in which patients treated surgically had greater 
dysfunction than patients treated by radiotherapy, and yet had similar global QoL 
scores. Weymuller et al in their prospective study of 210 patients also found that 
there was no difference in QoL between the chemoradiotherapy and laryngectomy 
treatment groups (38). Furthermore, Stoeckli et al compared patients with early 
laryngeal disease treated by laser with those treated by radiotherapy and found no 
significant differences in global QoL (40). This seems to suggest that at least some 
groups of patients can learn to cope with and adapt to dysfunction, given time and 
appropriate support measures. It should be remembered that longitudinal studies of 
2-years or more have less than 50% of the initial patient group surviving to 
contribute to the 2-year assessment. However, those that do survive seem to have 
adapted remarkably well to their disability or handicap. (Level 2). 
 
Survivors from the widely reported “VA study” of laryngeal cancer where patients 
were randomly assigned to combined surgery and radiotherapy or induction 
chemotherapy prior to radiotherapy or surgery have recently been reviewed for 
QoL outcomes (41). While the study was not designed to monitor QoL, the 
prominence of this particular study means that the results are viewed with great 
interest. Only 46 of 93 ‘known survivors’ were assessed, and speech function was 
found to be similar irrespective of laryngectomy status. Pain scores were less and 
emotion/depression scores were better in the patients in whom the larynx was 
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preserved. The results indicated that pain and psychosocial function were more 
important to patients’ QoL than speech. Unfortunately the cross-sectional nature of 
the QoL data and the incomplete follow-up raises many questions. 
 
Another important aspect of the effect of treatment on QoL is the impact of the 
mode of reconstruction (mainly in oral cancers) has on QoL. Because of the 
considerably greater effort and cost involved in revascularised tissue 
reconstruction, it is important to establish its efficacy and superiority over less 
complex reconstruction techniques to justify its routine use. Schliepake et al (34) 
has recently shown that revascularised fasciocutaneous flaps produced the 
greatest improvement in QoL, when compared to local flaps and myocutaneous 
revascularised flaps. Moreover, at 12 months, revascularised forearm flaps 
resulted in a higher QoL than at diagnosis. Myocutaneous revascularised flaps for 
large volume defects produced the lowest QoL scores, with QoL being significantly 
lower at 1 year than at diagnosis. [Level 2] 
 
 
Impact of Premorbid Patient Characteristics on QoL 
“Psychological interventions in patients with head and neck cancer that fail to take 
pre-existing problems into account may incorrectly focus on adjustment to illness”.   
Walter Baile, et al, 1993. 
 
It is likely that, if survivorship and QoL outcomes are similar between treatments, 
economic factors will become major determining factors in the treatment decision-
making process. One variable that may moderate that process, however, is the 
pre-morbid QoL profile of any particular patient. Very little information is available in 
relation to the premorbid characteristics of HNC patients.  
 
Demographic characteristics 
"Studies do not show a consistent difference between men and women [in QoL]… 
With regard to age, it is often assumed that elderly patients fare worse but few data 
support this view" de Graeff et al, 2000. 
 
Demographic information such as age, gender, vocation, work profiles, level of 
education and marital status is often reported but it is not clear what importance to 
place on these factors from the QoL point of view. At this stage there is no 
consistent evidence for any inter-group differences in QoL at diagnosis or as an 
outcome based on the aforementioned demographic patient variables (32,35)  
[Level 3]. 
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Alcohol and Tobacco 
“… Alcohol consumption …may not be perceived by the patients as having as 
much of an effect on health status as does medication …”   Erin M. McDonough, et 
al,  1996. 
 
The life-time alcohol and tobacco consumption of HNC patients has been widely 
reported, but these life-style parameters of social functioning do not necessarily 
reflect QoL or general well-being; and they often change (by choice) after treatment 
for HNC. This suggests that patients’ priorities alter after they discover that they 
have developed a malignancy. However, if patients are instructed to alter dietary 
habits (including reduction of alcohol consumption) after treatment for head and 
neck cancer, their compliance is not predictable (42). Some research suggests that 
the individuals who have less disruption to their lives – for example those who have 
less advanced disease or who undergo less invasive treatment – are the ones 
more likely to continue smoking (42), despite an increased risk of recurrence and 
death. Importantly there is evidence that alcohol intake ‘can provide important 
prognostic information’ in HNC, and that abstinence amongst alcoholic patients can 
lead to prolonged survival. (43) [Level 2&3] 
 
Sexual Functioning 
“As for sex, I didn’t think of my cancer of the larynx patients in terms of their 
sexuality.” Lawrence W. DeSanto.  1994. 
 
Some authors have investigated pre-treatment sexual functioning in HNC patients. 
De Santo et al (44) found that about two thirds of laryngeal cancer patients treated 
surgically cited no change or only a slight decrease in sexual interest after surgery 
but that about 20% of all patients reported serious sexual performance problems 
post-operatively. Presumably not all of the patients reporting ‘no-change’ were 
sexually active pre-operatively. Herranz and Gavilan (45) using the same 
instrument as DeSanto et al reported 55-60% of patients and their spouses had no 
change in their interest in sex and about 40% had no change in sexual activity. It is 
uncertain from these reports how sexual functioning – or a change in functioning – 
correlates with overall QoL or whether it should be recorded at the time of 
diagnosis. [Level 3] 
 
Coping Skills 
“From a clinical perspective, (the first area to) be considered in determining patient 
risk for psychological disturbance includes patient variables such as … coping 
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resources. It is likely that laryngeal cancer patients are at increased risk for 
psychological disturbance.”  Richard P McQuellon and Gail J Hurt. 1997. 
 
There is a gathering body of evidence to suggest that pre-existing abilities in 
relation to coping skills and stress management may well be important (1). The 
retrospective nature of most of the studies of coping means that only survivors are 
assessed and that the evidence is potentially biased or non-representative of the 
total population being studied. Baile et al (46) noted that HNC patients showed a 
more “repressive” coping style than non-cancer patients, with high scores on 
dependency and social conformity among the HNC group. This would explain the 
observation that married patients fare better than unmarried patients, and that over 
80% of laryngectomy patients who retain their circle of friends develop 
oesophageal speech whereas only 10% of those who lose all their friends regain 
speech. [Level 3] 
 
Langius et al (47) followed a group of oral and pharyngeal cancer patients 
prospectively for 12 months and found a strong positive correlation between 
patients' inherent coping ability - as measured by the sense of coherence - and 
psychosocial, physical, and home functioning, and eating disturbance.  De Boer et 
al (48) also showed in a cross-sectional study that the important factor in 
rehabilitation seemed to be not so much the treatment received - or the site of 
tumour (oral cavity versus larynx) - but rather the innate ability of patients to cope. 
This issue of patients’ coping abilities is quite pivotal, as the ability of an individual 
to adjust is determined at least in part by that person’s coping ability. Support for 
this notion comes from Italy (49) where it was found that the single most important 
factor in determining patients’ mental coping with disease was, after multivariate 
analysis, the time since treatment (less than, or more than 12 months). 
 
Psychological Factors 
“Heightened attention to the psycho-social concerns of patients treated for head 
and neck cancer will serve to … increase levels of compliance and maximize 
patient outcomes.” Erin M McDonough et al.  1996. 
 
Davies et al (22) examined the psycho-social aspects of patients prior to 
endoscopy for diagnostic biopsy and found that patients with cancer had a 
significantly higher rate of depression (29%) before biopsy than the group of 
patients whose biopsies were negative. Baile et al (46) also found a high rate 
(about 40%) of pathological anxiety and depression among HNC patients prior to 
biopsy, but found that patients with benign lesions were slightly more emotionally 
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disturbed and significantly more stressed. Baile et al suggested that cancer 
patients may minimise the seriousness of their problems, and that there is “a need 
to assess psychological status of these patients before treatment”. The very few 
prospective studies in this field show that depressive symptoms may be one of the 
significant pre-treatment predictors of QoL (36) [level 2]. For example, the 
psychological preparation pre-operatively also appears to be a major factor for 
post-operative adaptation and adjustment (50) .Moreover there is evidence now 
emerging that psychosocial intervention (in the form of long term psychological 
therapy) may result in significant improvements in QoL of HNC patients compared 
to controls (33,51,52). These findings have lead several authors to suggest that the 
identification of patients with depression should be routinely carried out, and 
interventions instituted as part of the rehabilitation program [Grade B].  
 
Cultural, religious and spiritual factors 
“75% of patients surveyed thought that their physicians should address spiritual 
issues as part of their medical care" Matthews et al, 1998. 
 
For many years QoL in HNC has been reported from different centres by authors 
who each used their own particular measure to record QoL. In recent years there 
has been wider utilisation of some of the QoL instruments by different centres 
which allows comparison between populations. Even so, there has been little or no 
attempt by authors to examine or explain differences between populations 
according to cultural differences. Some studies have reported multi-centre studies 
of QoL in HNC patients, but still there is a degree of cultural homogeneity in the 
study groups.  
 
The impact of religion and spirituality has recently been studied more closely. 
Studies show that they have a positive role in maintaining physical and mental 
health in times of stress and grief, and that 75% of HNC patients want doctors to 
address spiritual issues (53) [Level 3]. Doctors are not trained in enquiring about 
non-medical concerns of patients, and therefore may find it alien. However, routine 
questioning about the role of religion in the patient's coping mechanism, and how 
to support that, is to be encouraged [Grade B] (1).  
 
Social support 
"Social support …is thought to be a good predictor of subsequent well being" 
Collins, 2000. 
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As noted above, HNC patients appear to be more dependent on family and social 
support. Stam et al (54) found that satisfaction with social support and pre-
operative counselling by a laryngectomee predicted later satisfaction and higher 
QoL. They found that Natvig (27) identified 3 areas that were important QoL 
determinants. These were: individual patient coping skills, family support, and pre-
operative counselling of the patient and his family. Other studies have found similar 
findings. [Level 3] 
 
 
Performance status, Symptoms and Co-Morbidity 
"[Pre-operative] functional status …has been shown to be positively correlated with 
QoL" de Graeff, 2000. 
 
In the very good study by de Graeff et al (36), the baseline pre-treatment 
performance status (as measured by the Karnofsky performance status) was one 
of the significant predictors of QoL after treatment. Similar findings were reported 
by Hammerlid et al (55) in their study which found that physical functioning at 
diagnosis was an independent predictor of global QoL at three years post- 
treatment. [Level 2] 
 
Symptoms, whether from the tumour or from its treatment, may also determine 
QoL. Pain is a commonly reported correlate of QoL, and pain may be predictably 
related to treatment. For example, if the neck has been surgically treated, shoulder 
pain and discomfort will be worse than if no neck dissection is performed. Chaplin 
and Morton (56) showed that the prevalence of pain and discomfort was no 
different with the type of neck dissection although Kuntz et al (57) reported that the 
degree of discomfort and pain was more with radical neck dissections [level 3].  
 
Co-morbidity in the context of cancer is defined as a patient’s medical condition 
which is in addition to and distinct from their index cancer. Patients with head and 
neck cancer are likely to have co-morbidities, because they are usually older and 
have usually had high consumptions of tobacco and alcohol. Co-morbidities 
significantly affect head and neck cancer patient’s outcomes and survival (58-61) 
[Level 2]. This is partly because these co-morbidities interact with the patient’s 
cancer and its treatment, eg whether a patient is fit enough for a certain treatment. 
Co-morbidities can also affect survival independently- eg a patient may be cured 
from the HNC but die of heart failure. Co-morbidity may also be an independent 
determinant of QoL, especially the longer a patient survives (61). 
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Areas for future research 
- Clearer definition of QoL and consensus on how to measure it. 
- Randomised prospective trials with large numbers of patients with same site 
primaries, and the emergence of long-term prospective data 
- Assessment of impact of ethnicity, culture and spirituality. 
- Evaluation of reproducibility of disease – specific measures instead of 
development of new tools, and identification of best tools for particular 
circumstances. 
- More structured QoL assessment of organ preservation methods. 
 Is QoL enhanced by the following: selective neck dissections, organ 
preservation surgery, organ preservation chemoradiotherapy? 
- Clearer understanding and more regular assessment (eg by specialist 
counsellor) of contributing factors to well-being and determination of effects of 
intervention in these on QoL. 
 
 
Conclusions 
Assessment of quality of life in patients with head and neck cancer has improved 
our understanding of patients’ priorities and the patient journey during and after 
treatment. This has improved clinicians’ ability to provide patients with appropriate 
information regarding their condition and treatment, and to aid patients during the 
decision making process.  
 
There are further, potentially greater, benefits to come in future  however – these 
include better reporting formats of QoL studies, improving the follow-up 
consultation, screening patients for problems and initiating interventions to improve 
QoL. 
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Figure 1: Best research practice. 
 
 
 It is important to have a clear definition.  
 QoL studies should use patient self-reported data, which account for at least 
the four main domains, and which provide a patient-rated global QoL score, as 
well as disease-specific measures.  
 Studies should use existing validated  instruments, and should follow patients 
longitudinally from the time of diagnosis.  
 Additional information may be gathered from patients’ family members; and 
objective assessments of function - such as swallowing and speech - may be 
useful. 
 Future research to concentrate on validation of current measures, and on 
determining the most appropriate tools for particular situations. 
 
 
 
Figure 2: Best clinical practice  
 
 
 Identification of patients with depression and alcoholism should be routinely 
carried out, and interventions instituted as part of the rehabilitation program 
 Routine questioning about the role of religion in the patient's coping 
mechanism, and how to support that, is to be encouraged 
 Pre-operative counselling by a laryngectomee is important. 
 
 
 
Figure 3:  Practical points to enhance QoL of your HNC patients + 
 
 
 Assess QoL before cancer treatment instituted. 
 Screen for depression and alcoholism , and develop a treatment plan since this 
has positive effect on QoL. 
 Consider the impact of religion and spirituality. 
 Empower patients - give patients sense of control by involving them in 
decision-making.  
 Set realistic expectations, and avoid over-optimistic outlooks. 
 Offer patients opportunity to talk to pts who had treatment- found to be one of 
the most effective interventions to increase QoL. 
 Use the most oncologically effective treatment first, then make modifications 
that can optimise QoL, eg parotid sparing post-op radiotherapy.  
 Get involved in patient groups and post-treatment educational and support 
groups. 
 
+ adapted from Collins (1) 
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Table 1: Features of the QoL phenomenon in cancer patients. 
 
 
 
Operational Characteristics 
 
Essential Components/ 
Domains 
QoL assessments must be self-administered Physical function 
QoL is subjective, but quantifiable Psychological state 
QoL is multifactorial, or multidimensional Social interaction 
Overall QoL (and each dimension’s value)  
varies over time Somatic sensation 
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Table 2: Guidelines for the development and implementation of QoL 
questionnaires in cancer patients (15,54).  
 
1 Decide the Hypothesis to be 
tested  
2 Decide on definition of 
Quality-of-life to be used  
3 Disease-specific 
questionnaire  to include: 
Disease and Treatment-related symptom scores; 
Health and Disease-status 
4 Patient data to be self-
reported  
5 Enquiry on domains of 
functional status to include: 
 
 
Psychological functioning  
Socio-sexual functioning 
Physical functioning  
Global QoL measure (patient-generated) 
6 Field testing and fine-tuning 
of questionnaire  
7 Instruments should have 
proven, or be checked for: 
Reliability 
Validity 
Responsiveness/Sensitivity 
8 Design longitudinal study   
 
 
 
Table 3: Terms used to describe the various forms of validation that a QoL 
questionnaire must exhibit (30,62) 
 
Psychometric 
criterion 
Biomedical 
terminology 
meaning 
Content validity Comprehensiveness Questions cover relevant issues 
Face validity Credibility Questions are clear   
Criterion validity Accuracy Performance of instrument in 
comparison to a ‘gold standard’ 
Discriminant 
validity 
Responsiveness Ability and sensitivity to detect 
change. 
Construct 
validity 
Biological sense Ability of instrument to behave in a 
fashion consistent with a theoretical 
framework 
Reliability Reproducibility Ability to produce similar results on 
retesting 
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Table 4: characteristics of commonly used QoL instruments # 
 
 
 EORTC 
QoLQ 
C30/ 
H&N35 
FACT-
G/H&N 
HNRQ QoL- 
H&N 
QoLQ QoL-  
RTI/HN 
HN 
QoL 
UW 
QoL 
General (G) or  
specific (S) 
both both S both S both S S 
Validated + + +/- +/- +/- +/- +/- + 
No of items 65 27 22 29 19 39 21 12 
No of  
domains  
6 4 6 3 4 5 4 9 
Self-
administer 
+ + - + + + - + 
Global 
measure 
+ - - + - + + + 
Summary 
score 
- + + - ? + - + 
Cross-cultural 
validation/ 
translation 
+ 
several 
languages 
+/- 
ongoin
g 
- - - +/- 
Japanese
, 
German, 
Spanish 
- - 
Scoring C30- B 
HN35-W 
B B B ? ? B B 
Time to 
complete 
18 5 10 15 ? ? 11 short 
 
# adapted from review by Ringash and Bezjak (9) 
+ means criterion present or proven, - means not present or not yet proven; +/- means 
limited or partial proof available; ? means not assessable;  
B means the higher the score, the better the QoL; W means the higher the score, the worse 
the QoL or symptom. 
EORTC QoLQ C30/H&N35: European Organisation for Research and Treatment of Cancer 
Quality of Life Questionnaire for Head and Neck Cancer C30/H&N35;     FACT – G/H&N : 
Functional Assessment of Cancer Therapy-General/Head and Neck 
HNRQ : Head and Neck Radiotherapy Questionnaire; QoL-H&N: Quality of Life Instrument 
for Head and Neck Cancer; QoLQ: Quality of Life Questionnaire for Advanced Head and 
Neck Cancer; QoL-RTI/H&N: Quality of Life –Radiation Therapy instrument Head & Neck 
Module; HNQoL: University of Michigan Head and Neck Quality of Life; UWQoL: University 
of Washington Quality of Life Questionnaire 
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Table 5: purpose and uses for which instrument was developed. # 
 
 
Instrument 
Stated 
Purpose  
 
Uses 
 
EORTC QoLQ C30/ H&N35 D, E For use in HNC patients in all stages, 
acute or chronic, treated or untreated 
FACT-G/H&N D, E For descriptive, discriminative and 
evaluative use. 
HNRQ E To measure radiation induced acute 
morbidity and QoL in HNC patients. 
QoL-H&N D, E To be a short sensitive, disease specific 
questionnaire with emphasis on 
psychological factors. 
QoLQ E To discriminate between patients with 
advanced HNC undergoing radiotherapy 
alone or surgery and radiotherapy   
QoL-RTI/HN E Very specific for measuring QoL in 
patients undergoing radiotherapy 
HNQoL D, E Overall assessment of disease specific 
QoL in HNC patients 
UW QoL D Intended primarily for patients undergoing 
surgery 
 
# adapted from review by Ringash and Bezjak (9) 
D means discriminative purpose, E means evaluative purpose. 
EORTC QoLQ C30/H&N35: European Organisation for Research and Treatment of Cancer 
Quality of Life Questionnaire for Head and Neck Cancer C30/H&N35;   FACT – G/H&N : 
Functional Assessment of Cancer Therapy-General/Head and Neck 
HNRQ : Head and Neck Radiotherapy Questionnaire; QoL-H&N: Quality of Life Instrument 
for Head and Neck Cancer; QoLQ: Quality of Life Questionnaire for Advanced Head and 
Neck Cancer; QoL-RTI/H&N: Quality of Life –Radiation Therapy instrument Head & Neck 
Module; HNQoL: University of Michigan Head and Neck Quality of Life; UWQoL: University 
of Washington Quality of Life Questionnaire. 
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Abstract 
Objectives: 
1. Determine 10 year Quality of life (QoL) in head and neck cancer (HNC) 
patients 
2. Examine the potential predictors of late QoL 
 
Design: prospective 10 year (QoL) assessment in a cohort of HNC patients. 
 
Setting: tertiary referral head and neck cancer centre in Auckland, New Zealand 
Participants: 200 patients diagnosed and treated for HNC. Exclusion criteria were 
blindness, learning difficulties or inability to understand or read English.  
 
Main outcome measures: QoL at 10 years measured by Auckland QoL 
questionnaire, and analyzed for associations with the following co-variates: age, 
gender; co-morbidities (alcohol intake and smoking), type and stage of disease; 
treatment modality; and QoL measures. 
 
Results: At 10 years following diagnosis, overall QoL (Life Satisfaction score) 
decreased significantly by an average of 11% (95% CI -5%, -17%) compared to 
before treatment, and by 15% when compared to years one and two.  Pre-
treatment QoL significantly predicted late QoL, whilst QoL 1 year after treatment 
did not. None of the socio-demographic, disease or treatment related factors 
predicted long-term QoL on univariate analysis, but this may be due to the small 
sample size. 
 
Conclusions: This observed late drop in the QoL of HNC patients requires further 
corroboration and investigation. Due to small sample sizes associated with long-
term studies in HNC cohorts, studies of predictors of long-term QoL will only be 
likely to succeed if done as multi-centre studies. As there is some evidence to 
suggest that psychosocial interventions improve the QoL of HNC patients, it may 
be appropriate to consider screening for risk of a late deterioration in QoL in order 
to plan appropriate psychosocial intervention. 
 
Introduction 
The importance of health–related quality of life measurement in patients with head 
and neck cancer is now well recognised, due to the significant effect of the disease 
and its treatment on their functional and psychological states. Since the different 
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treatment modalities may result in similar survival rates but different types of 
functional effects (1,2), health–related quality of life also plays a role in 
differentiating and choosing between treatment modalities.  
 
Over the past two decades, there has been a rapid increase in studies on health – 
related quality of life in head and neck cancer (3). Initially studies of quality of life 
were retrospective and cross-sectional, using non-validated measures with the 
inherent methodological inadequacies. More recently, we (4) and others (5-8) have 
reported prospective quality of life studies with medium-term (2-3 years) follow-up. 
These have demonstrated that patients’ quality of life usually decreases during 
treatment, but that generally, it starts improving 3-6 months after treatment to reach 
or exceed the pre-treatment level by the end of the first year.  Quality of life 
appears to continue to improve slightly for the following two - three years (4-11).  
 
It is recognised however that quality of life measurement has to be long-term, as 
well as prospective, since clinical follow-up and survival statistics for head and 
neck cancer are normally based on five - year data, and a proportion of patients 
live 10 years or more.  Therefore, long-term measurement is necessary to 
characterise the quality of life, residual deficits and the late side effects of treatment 
in those who are cured. Some cross-sectional quality of life outcomes in long-term 
head and neck cancer survivors have been published (12-15), but these had no 
pre-treatment or early post-treatment measures for comparison – thereby 
considerably limiting the utility of the data. To date, no longitudinal quality of life 
data beyond 5 years is available in the literature. This is in part due to the 
difficulties encountered in conducting long-term trials in head and neck cancer, and 
in part due to the effect of patient attrition on small sample sizes. 
 
For the same reasons, predictors of long-term or late quality of life (5 years or more 
after diagnosis) have remained largely undefined. Determination of these 
predictors is important to attempt to identify means of improving the long-term 
quality of life of the patient, not only for the patients’ wellbeing, but also because 
there is increasing evidence that there may be a survival benefit (16). There are a 
large number of potential predictors or risk factors under study. The literature 
demonstrates associations between quality of life following treatment for head and 
neck cancer and tumour site (17,18), size (17-19) and type of treatment (19-23). 
Some researchers have also demonstrated that patient related factors (age, 
gender [21-23]), employment (24,25), marital status (18), and co- morbidities (26) 
predict quality of life. Patient behaviour, namely alcohol intake and smoking, has 
also been shown to be associated with quality of life in head and neck cancer by 
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some (27-28), but not by others (29-31). Understandably, psychosocial factors, 
especially depression, have also been shown to be associated with quality of life in 
head and neck cancer (29-32). 
 
The conflicting nature of the literature on predictors of quality of life in head and 
neck cancer is the result of several factors that complicate research in head and 
neck cancer in general. These complicating factors are:  
a. small sample sizes due to a low incidence rate and a large number of primary 
sites. Due to the small sample sizes, multi-variate analysis is usually not possible, 
and 
b. the need to analyse multiple potential predictors, some of which are related and 
hence suffer from confounding, and finally  
c. the duration of follow-up varies considerably between studies, and since time of 
measurement may have a significant influence on the quality of life being studied, 
this confounds the situation further. 
 
This study reports quality of life data from a prospective ten-year follow-up of a 
cohort of head and neck cancer patients, and examines the potential predictors of 
late quality of life, including demographic and patient related factors, disease and  
treatment related factors, and quality of life / psychosocial factors. 
 
 
Methods 
PATIENTS 
Two hundred patients with primary epithelial head and neck cancer, attending a 
head and neck clinic in tertiary referral centre in Auckland, New Zealand, were 
recruited to a two year prospective quality of life study from 1989 – 1992 (4). 
Patients with blindness, learning difficulties or inability to understand or read 
English were excluded. The survivors of this cohort were traced 10 years after 
diagnosis through a national hospital tracking system, through contact with their 
family doctors and by using their last known address and / or next of kin.   
 
DATA COLLECTION AND ETHICAL CONSIDERATIONS 
Appropriate approval from the local ethics committee was obtained. Consenting 
was performed by a trained clinic nurse, who also gave assistance with completion 
of the questionnaire if required.  
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Patients completed the Auckland Quality of Life Questionnaire at diagnosis, and at 
three, twelve and 24 months as part of the two year prospective quality of life study 
from 1989 – 1992 (4). At 10 years, the surviving patients were asked to complete 
the Auckland Quality of Life Questionnaire again to provide the 10 year follow-up 
data.  
 
AUCKLAND QUALITY OF LIFE QUESTIONNAIRE 
The Auckland Quality of Life Questionnaire (4) is a validated, patient-reported, 
composite health-related quality of life measure, comprised of the three the 
instruments detailed below: 
 
LIFE SATISFACTION SCORE (LS) 
This is a well established psychometric tool measuring general well being. It is self-
reported and consists of two parts: 
a. Single item ‘life as a whole these days’ representing overall (global) score of 
life satisfaction. This has a 7 point Likert scale, ranging from extremely 
dissatisfied (scores 1) to extremely satisfied (score 7). 
b. Aggregated 10 item score relating to social, family and general physical 
function. The individual items are scored using the same seven point Likert 
scale above, and the scores are then summated to form an aggregated score ( 
minimum 10, maximum 70). The higher the score, the greater the satisfaction. 
Further validation has suggested that the aggregated score is more sensitive 
measure of global quality of life than the single item measure, and hence has 
been used as the dependent variable in the analysis of this study (4,33). 
 
GENERAL HEALTH QUESTIONNAIRE (GHQ)-12 
This is a well established, patient self-reported, psychometric instrument that 
measures psychological distress. It is often used as a screening tool for unmet 
psychosocial needs, and has previously been used in studies of head and neck 
cancer (4, 33). The GHQ focuses on interruptions in normal psychological function, 
rather than on lifelong traits.  The GHQ was scored using the 4-point Likert scale 
rather than the alternate condensed 2-point option, with each of the 12 items being 
a question with a four point Likert response (score 0-3). The item scores are 
summated (score range 0-36).  
 
55 
Chapter 3 
HEAD AND NECK SYMPTOM QUESTIONNAIRE 
This consists of 5 items concerning disease and treatment related symptoms - 
head and neck pain, shoulder and arm pain, speech difficulty, swallowing difficulty 
and cough. Scores range from 1 to 5, with 1 being most severe symptoms, and 5 
being no symptoms at all. 
 
ANALYSIS 
The dependent variable for this study was overall quality of life (as measured by 
the aggregate Life Satisfaction score) at 10 years following diagnosis. This was 
analyzed for associations with the following co-variates: socio-demographic factors 
(age, gender); co-morbidities (alcohol intake and smoking), tumour characteristics 
(type and stage of disease); treatment modality; and quality of life measures. The 
latter included overall quality of life, psychological disability and physical disability 
measures, both at diagnosis and 12 months later. For ease of interpretation, 
continuous risk factors in the final models eg Life Satisfaction score and GHQ in 
Table 4, were expressed using categorical classifications, since it had been 
established that the results were not sensitive to continuous or categorical 
expression. These categorical classifications were selected using the score of the 
upper quartile as the cut-off point, so that the upper quartile group was compared 
with the rest of the sample. The Mann Whitney U test was used to examine 
statistical differences (p<0.05) between subgroups in co-variate analyses. Due to 
the small sample size, multi-factorial analyses were not performed. 
 
RESULTS 
PATIENTS CHARACTERISTICS 
At ten years, 136 (68%) patients were deceased, and 50 (25%) patients were 
confirmed alive, of whom 43 were successfully contacted. Two had moved 
overseas, 2 could not be contacted, 2 declined participation, and one was excluded 
due to dementia. The status of 14 (7%) was unknown. All 43 contacted patients 
were disease free. 
 
The ten-year survivors were on average four years (SD  1.7) younger at 
recruitment than non-survivors, and were more likely to be male (86% in 10 year 
survivors versus 76% in the inception cohort), have glottic carcinoma and have 
early (stage I) disease (37% vs. 18% respectively) [See table 1].  Only 9% of 
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survivors had advanced stage IV disease at presentation compared to 35% of 
original cohort. 
 
MAIN QUALITY OF LIFE PARAMETERS 
At 10 years following diagnosis, overall quality of life (Life Satisfaction), had 
decreased significantly by an average of 7 points (95% CI –3,–11), that is a drop of  
11% for the 10 year survivors compared to baseline before treatment, and a 
decline of 15% when compared to years one  and two scores (see figure 1). 
Psychological distress (as measured by General Health Questionnaire) had 
worsened on average by 3 points (95% CI –1,-5), or a 9% decrease, and by more 
(15%) when compared to the one and two year scores (see figure 2). All head and 
neck symptoms deteriorated by 0.4 to 0.8 points, representing 10-20% change, 
compared to baseline; the largest declines occurring for shoulder/arm pain, head 
and neck pain and coughing (see table 2 and 3). All the above changes in Life 
Satisfaction, GHQ and symptom scores are mirrored to a similar, but slightly lesser 
degree, by the changes reported by the overall cohort (see tables 2 and 3). 
 
PREDICTORS OF QUALITY OF LIFE 10 YEARS FOLLOWING TREATMENT 
None of the socio-demographic (gender, age, smoking and alcohol status), disease 
(stage and site) or treatment related factors predicted long-term quality of life. Pre-
treatment quality of life significantly predicted late quality of life, whilst quality of life 
1 year after treatment did not (see table 4). Psychological distress prior to 
treatment did not predict long-term quality of life, whereas psychological distress 
after treatment had a significant association with poorer long-term quality of life 
(see table 4). Pre-treatment speech was the only symptom measure to significantly 
predict long–term health-related quality of life, where those with better speech pre-
treatment showed larger deteriorations in their long-term health-related quality of 
life.   
 
Discussion 
KEY FINDINGS 
Considering that in the first two years, patients’ quality of life recovered and often 
exceeded baseline, the late deterioration in quality of life among long-term 
survivors of head and neck cancer has not been previously reported and is 
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unexpected, especially when taking into account that these patients had generally 
presented with early stage disease that was controlled by single modality therapy.  
 
This late decrease in quality of life and worsening of psychological status may be 
related to a late anxiety or anger reaction, as has been previously reported in a 
cross-sectional study (12). Alternatively, it may be a reflection of a perceived loss 
of interest in, attention to, or sympathy with, the patient from medical staff or family 
after the patient’s discharge from follow-up (usually at five years after treatment). 
Furthermore, patients did report deterioration of their head and neck symptoms, 
possibly due to late effects of treatment or deteriorating health and increasing co-
morbidities with advancing age. Although there was no significant association 
detected in the study, this worsening of symptoms may possibly have resulted in 
the deterioration in quality of life and psychological status. Other possible 
explanations may include regression to the population mean quality of life, 
following early post-treatment euphoria at tumour control.  
 
LIMITATIONS OF STUDY 
Several factors should be taken into consideration. Due to the large gap between 
the time points investigated, the study fails to identify the point at which the 
patients’ quality of life starts to deteriorate. Is it gradual, or precipitous? Secondly, 
as with all prospective trial in cancer, there is an inherent selection as the study 
only involves survivors, whom, as one might expect, had better quality of life at 
every point compared to the remainder who did not survive (figure 1).   
Furthermore, most of the survivors are patients who had early stage disease which 
was controlled by single modality treatment, and therefore findings, especially 
comparisons between subgroups, may be biased by this predominance. In 
addition, due to the nature of the disease, only 25% of patients are alive by 10 
years. This has a bearing on the number of surviving participants in such a long-
term trial, and may result in analysis bias due to sample size being too small to 
show significant differences in sub-group factorial analyses. Therefore the results 
of the analysis of possible predictors should be interpreted with caution. This is 
also the reason that a multivariate analysis of possible predictors was not 
performed, as it would have been meaningless with small numbers.  
 
COMPARISON WITH OTHER STUDIES 
The above reasons may also explain some of the variable findings of our study. For 
example, demographic, disease and treatment factors did not predict long-term 
58 
Deterioration of QOL of late suvivors 
 
quality of life. This is at variance with some of the published literature (18-23) as 
discussed previously. However, these studies mainly looked at short- and medium 
- term quality of life, and hence the variance with our study may be explained by 
the length of follow-up. Our study examines quality of life at 10 years, which may 
be determined by new factors that developed in later years (for example co-
morbidities and unmet needs), and which were not present before treatment or in 
the early post-treatment phase. Analysis bias should also considered, since as 
expected, most surviving patients were a homogeneous group – early laryngeal 
disease treated by radiotherapy- and hence there may be no significant differences 
between such a homogenous group.  
 
Many longitudinal studies of quality of life and other factors in head and neck 
cancer patients show deterioration in the quality of life of patients at 3 months (5-8). 
In our study, psychological distress worsened at 3 months, but the overall quality of 
life did not deteriorate. We are unable to explain this difference, but the issues 
discussed above may be contributing to this. However, the changes in quality of life 
at the other time points (1 and 2 years – which are the ones that we have used in 
our analysis) reflect the findings of the other studies.   
  
We had hypothesised that long-term quality of life was likely to be influenced more 
by the steady state quality of life that the patient reaches after experiencing and 
adapting to their disease and subsequent treatment than by their quality of life 
before treatment. Hence, we had postulated that quality of life one year after 
treatment may be a stronger determinant of long–term quality of life than pre-
treatment quality of life. While the study did show an association between 
psychological state at 1 year and long-term quality of life, the findings regarding 
overall quality of life did not confirm our hypothesis. The reasons for these findings 
are not obvious, but again all the above arguments may be potential explanations. 
 
CLINICAL RELEVANCE 
There is emerging evidence that quality of life may be associated with long-term 
survival in head and neck cancer (34), and some evidence that psychosocial 
interventions may improve patients quality of life (35). Therefore it may be 
appropriate to consider screening long-term survivors for quality of life deterioration 
so as to enable detection and appropriate intervention. 
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Conclusions 
This late drop in the quality of life of head and neck cancer patients has not been 
observed previously, and requires further corroboration and investigation. Due to 
small sample sizes associated with long-term studies in head and neck cancer 
cohorts, studies of predictors of long-term quality of life will only be likely to 
succeed if done as multi-centre studies (with consideration for the effects of culture 
on quality of life (4)).  
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      Table 1.  Baseline characteristics of study group and 10 year survivors. 
 
All patient cohort 
n=200 
10 yr survivors 
n=43 
Demographics and co-morbidites   
  Male 152 (76%) 37 (86%) 
  Age 64  11.9 60  10.5 
  Alcohol consumption nearly/every day 67 (34%) 13 (31%) 
  Ever smoked 170 (85%) 35 (83%) 
Disease Status   
  AJCC Stage   
  I 35 (18%) 15 (36%) 
  II 30 (15%) 8 (19%) 
  III 45 (22%) 12 (23%) 
  IV 69 (35%) 4 (9%) 
     unknown 21 (10) 4 (9) 
  Nodal involvement 86 (43%) 10 (24%) 
  Tumour Site   
  Supraglottis 29 (15%) 3 (7%) 
  Glottis 47 (24%) 19 (45%) 
  Oro/naso/hypopharyx 64 (32%) 7 (17%) 
  Oral 26 (13%) 6 (14%) 
  Other 34 (17%) 7 (17%) 
  Treatment   
  Surgery 32 (16%) 9 (21%) 
  Radiotherapy 64 (32%) 16 (38%) 
  Surgery & Radiotherapy 81 (41%) 16 (38%) 
      unknown 23 (11%) 2 (5%) 
  Neck dissection 64 (32%) 10 (24%) 
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Table 2:  All patient cohort symptom scores and change over time  
Mean baseline  standard deviation and change (95% confidence interval) in symptom scores. 
 
 Mean Change from Baseline (95% CI) at Baseline 
N=200 
(mean  sd) 
3 months 
n=173 
12 months 
n=139 
24 months 
n=95 
10 years 
n=43 
Coughing 7  1.3 -0.2 (-0.42, 0.07) 0.1 (-0.05, 0.49) 0.1 (-0.04, 0.59) -0.4 (-1.17, -0.21)
Speaking difficulty 4.6  0.8 -0.5 (-0.64, -0.26) -0.4 (-0.55, -0.14) -0.1 (-0.34, 0.09) -0.4 (-0.81, -0.46)
Head and neck pain 4.1  1.1 0.1 (-0.11, 0.27) 0.2 (0.02, 0.41) 0.4 (0.10, 0.61) -0.3 (-0.76, 0.05) 
Shoulder and arm pain 4.8  0.6 -0.4 (-0.55, -0.26) -0.4 (-0.55, -0.24) -0.3 (-0.48, -0.07) -0.8 (-0.15, -0.46)
Swallowing difficulty 4.2  1.2 -0.2 (-0.40, -0.02) -0.2 (-0.42, -0.02) -0.1 (-0.32, 0.15) -0.6 (-0.93, -0.21)
 
sd = standard deviation, CI = confidence interval 
Symptom scores range from 1 to 5 where 1 indicates severe pain/difficulty and 5 no pain/difficulty.  
Change calculated as: time period – baseline scores. 
A negative mean change indicates a deterioration in symptoms, a positive mean change indicates an improvement in symptoms. 
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Table 3: Quality of Life outcomes of 10 year survivors over time (n=43). 
 
 
Mean score (95% CI) 
Life Quality Measure  
(score range) 
Baseline 
  
1 year 
  
2 year 
  
10 year 
  
Life Satisfaction (10-70) 60.8 (59,62.7) 64.1 (62.1,66) 63.2 (60.9, 65.6) 53.6 (50.7,56.6) 
Global Satisfaction (1-7) 6.21 (6.1, 6.4)  6.4 (6.5,6.9) 6.41 (5.9,7.0) 5.7 (5.2,6.2) 
GHQ (0-36) 21.44 (19.1,22.6) 19.9 (18.6, 20.1) 19.0 (16.6, 21.7) 21.14 (19.34, 20.04) 
Head and Neck symptoms    
   Coughing (1-5) 4.0 (3.6,4.3) 4.0 (3.7,4.4) 4.1 (3.7,4.4) 3.3 (3.0,3.6) 
   Speaking (1-5) 4.6 (4.4,4.8) 4.5 (4.2, 4.8) 4.7 (4.5,4.8) 4.1 (3.8,4.6) 
   Head/Neck pain (1-5) 4.3 (4.0,4.6) 4.5 (4.2,4.7) 4.6 (4.4,4.8) 3.9 (3.6,4.2) 
   Shoulder/arm pain (1-5) 4.7 (4.6,4.9) 4.4 (4.2,4.7) 4.7 (4.5,4.9) 3.9 ( 3.6,4.3) 
   Swallowing (1-5) 4.7 (4.4,4.9) 4.5 (4.2,4.7) 4.4 (4.1,4.7) 4.1 (3.8,4.4) 
 
GHQ scores range from 0-36, where 0  is most least distress and 36 is most distress. 
            Symptom scores range from 1 to 5 where 1 indicates severe pain/difficulty and 5 no pain/difficulty. 
Chapter 3 
Table 4.  Association between long-term QoL  and QoL measures before 
               treatment and one year after diagnosis for 10 year survivors ( n=43). 
   Median Change   
      in LS p value* 
Quality of Life Status   
Life Satisfaction Score   
 Pre treatment   
  > 64  -11.5 (-17, -8) 
  <= 64 -3 (-9, 6) 
0.001 
 1- year   
  > 64 -5 (-13, 2) 
  <= 64 -8 (-16.5, -1.5) 
0.417 
General Health Questionnaire   
 Pre treatment   
  > 24 -7.5 (-11, 4.5) 
  <= 24 -6 (-13, 1) 
0.717 
 1- year   
  > 24 -11.5 (-16.5, -4.5) 
  <= 24 -5 (-10, 2) 
0.015 
Cough    
 Pre treatment   
  Occasionally/rarely -8 (-15, -3) 
  Constantly/most days  2 (-9, 6) 
0.058 
 1-year   
  Occasionally/rarely -5.5 (-11.5, 1) 
  Constantly/most days -6 (-11, 6) 
0.753 
Speaking    
 Pre treatment   
  No/little difficulty -8 (-13, -2) 
  Moderate/great difficulty  4 (-1, 8.5) 
0.033 
 1-year   
  No/little difficulty -5 (-10, 2) 
  Moderate/great difficulty -9 (-18, 1) 
0.300 
Head/Neck Pain    
 Pre treatment   
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Nil/slight -8 (-14, 1) 
  moderate/extreme -4 (-5, 7) 
 
 
0.078 
 1-year   
  Nil/slight -5 (-10, 2) 
  moderate/extreme -11 (-18, -4) 
0.142 
Shoulder/Arm Pain   
 Pre treatment   
  Nil/slight -6 (-13, 1) 
  moderate/extreme -2 (-10, 6) 
0.672 
 1-year   
  Nil/slight -5 (-10, 2) 
  moderate/extreme -10 (-18, 6) 
0.638 
Swallowing Difficulty    
 Pre treatment   
  Nil/slight -7 (-13, 1) 
  moderate/extreme  1 (-8, 9.5) 
0.210 
 1-year   
  Nil/slight -5 (-11, 2) 
    Moderate/extreme -9 (-18, 2) 0.598 
 
Key (table 4): 
 
*p value comparing two subgroups, using Mann Whitney U test. 
LS = aggregated life satisfaction score, compares upper quartile group ( with LS score over 
64) to rest of sample ( LS 64 or under) 
General health questionnaire (GHQ) score  compares upper quartile group ( with GHQ score 
over 24) to rest of sample ( GHQ 24 or under) 
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Figure 1: Average Life satisfaction (overall QL) scores for study cohort (──) and ten year 
survivors (- - -) over time. 
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Figure 2: Psychological distress (measured by average General Health Questionnaire 
(GHQ) scores) for study cohort (──) and ten year survivors (- - -) over time.   
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Abstract 
Objective: Assess whether pre-treatment and post treatment quality of life (QOL) 
was associated with long-term survival in head and neck cancer (HNC) patients. 
 
Design: 10-year follow-up of inception cohort.  
Setting: Regional tertiary referral centre. 
Participants: 200 consecutive patients with primary epithelial head and neck 
cancer.  
 
Methods: Quality of life and several recognized risk factors for mortality were 
assessed prospectively, using the Auckland QOL questionnaire, prior to treatment 
and 12 months post treatment, and survival was determined at 10 years. 
 
Outcome measures: survival, odds of mortality (hazards ratio). 
 
Results: At 10 years 136 (68%) were deceased, 48 (24%) were confirmed alive 
and the status of 16 (8%) was unknown. Median survival: 6 years (IQR 4.4, 7.7). 
Prior to treatment those with low quality of life had no significantly increased odds 
of mortality (hazard ratio [HR] 1.4 (95% CI 0.8, 2.4)). In contrast, post-treatment, 
those with low quality of life at 1 year had significantly increased odds of mortality 
[2.5 (95% CI 1.4, 4.3, p=0.001) even after adjustment for co-variates.  
 
Conclusions: The findings suggest potential survival benefits from improvements in 
QoL. However, the observed associations between survival benefit and 1 year QoL 
may be confounded by co-morbidity, which was not measured, and this deserves 
further investigation.  
 
Introduction 
Over past 20 years there has been an increased awareness of quality-of-life (QoL) 
as an outcome measure of cancer management (1). More recently, there has been 
a lot of interest in QoL as a predictor of survival. Strong associations between 
overall quality of life, a variety of QoL variables and short-term mortality have been 
reported in patients with a variety of advanced palliative-intent cancers (2), 
including breast (3), lung cancer (4,5,6) and melanoma (7). However, QoL 
variables predicting survival in such patients may not be relevant when considering 
long-term survival in patients treated with curative intent.  
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Therefore, studies evaluating the relationship of QoL with long-term mortality have 
been published. They are however much fewer in number due to the difficulties 
associated with conducting long-term longitudinal studies (8). These studies have 
shown variable and sometimes contradicting results, with some demonstrating a 
strong clear association between overall QoL and long-term survival (9,10,11), 
whilst others demonstrate no relationship at all (4) or a relationship with only one 
component QoL variable (13,14,15). 
 
 For head and neck cancer, the limited evidence available suggests that 
pretreatment overall QoL and long-term survival are not associated (16). However, 
studies have found associations between long- term survival and individual 
variables, such as cognitive functioning (16), fatigue (17) and perceived self- 
efficacy (18).  To date, no studies have examined the role of QoL after treatment, 
once patients have adapted to their diagnosis and treatment effects, in predicting 
long – term survival.  
 
These apparent inconsistencies in quality of life research in HNC patients raise 
important questions. Does poor quality of life increase the risk of mortality in the 
long term, or is it a surrogate for other risk factors, such as tumour site and stage?  
And since quality of life significantly changes after treatment, would quality of life 
post treatment be a more accurate prognosticator for long-term survival?  
 
This report describes an analysis of the association between quality of life prior to 
and one year post treatment with long-term survival in a cohort of HNC patients. 
Several other factors that could impact on this relationship were also analyzed. 
These included socio-demographic factors, alcohol intake and smoking history, 
disease characteristics, treatment, and psychological and functional disability. 
 
Methods 
STUDY POPULATION 
A cohort of 200 patients with primary epithelial HNC were recruited for a 
prospective QoL study after written informed consent was obtained by a trained 
nurse, as approved by the local ethics committee. The exclusion criteria were 
inability to understand or read English, blindness and learning disabilities. The 
cohort was followed up for ten years. 
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DATA COLLECTION 
Patients completed a quality of life questionnaire at diagnosis. Twelve months later,  
those patients free of recurrence completed the same QoL questionnaire again. At 
diagnosis, the following risk factor data was also collected: age, gender, alcohol 
intake, smoking status, disease type and stage (according to the American Joint 
Committee on Cancer Classification [19]) and subsequent treatment. 
 
QUALITY OF LIFE MEASURES 
The Auckland Quality of Life Questionnaire (AQLQ) was used in this study. It is 
self-reported, patient-oriented and validated (see previous publications for further 
details - 20-22), and is a composite of 3 questionnaires. The first, the Life 
Satisfaction Score (LSS), is a measure of general well-being, and is considered a 
reliable measure of overall QoL (20). It consists of ten questions, each with a Likert 
1-7 scale. The ten scores are summated to give an aggregated score, with a range 
of 10 (poorest) to 70 (best QoL).  
The second component is the General Health Questionnaire (GHQ). This is a well-
validated instrument that measures psychological distress (20,21). We used the 
12-item version with an aggregated score, ranging between 0 (no distress) to 36 
(maximum distress). The final component of the Auckland QoL questionnaire is the 
Functional Ability Questionnaire (FAQ), which enquires about the severity of 
several important HNC physical symptoms: cough, speech and swallowing 
difficulties, head and neck pain, and shoulder pain. For the purposes of clarity 
during the reporting of this study, some FAQ scores have been reversed where 
appropriate, so that the direction of all scores measuring physical symptoms 
coincide, that is, higher scores denote better function and less severe symptoms. 
 
END POINTS 
The primary outcome measure for this study was all cause mortality. This was 
determined from patients' clinical notes, a centralized national clinic booking 
system, the patient’s last recorded address, family doctor or next of kin. 
 
STATISTICAL ANALYSIS 
Associations between quality of life and other baseline characteristics were 
examined with logistic regression (with low/not low quality of life as the outcome 
measure). Cox proportional hazards regression analysis with time-constant 
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covariate were used to examine associations between baseline variables and all 
cause mortality, as well as QoL one year after diagnosis and all cause mortality.  
The proportionality of hazards was assessed by plotting Schoenfeld residuals (23) 
against each covariate, and no significant departures from the base model were 
discovered. The results are reported as hazard ratios and 95% confidence 
intervals. The nature of the associations between low quality of life (at both 
baseline and at one year) and mortality were examined using a linear term, 
quintiles and a binary measure in the models. For ease of interpretation, 
continuous risk factors in the final models were expressed using categorical 
classifications since it had been established that the results were not sensitive to 
continuous or categorical expression. When analyzing the association between 
one year QoL and mortality (Table 4), patients who had died before 12 months 
were of course excluded.  
 
Results 
OVERALL SURVIVAL 
At 10 years, 136 (68%) of the 200 patients were deceased. Of the remaining 64, 48 
participants were confirmed alive and the status of 16 could not be determined.  
The overall median survival was 6 years (95%CI 4.4, 9.1) (Figure 1). For the one 
year assessment, three patients had recurrent disease and received palliative 
treatment, and data was available for 137 out of 140 patients who were alive at one 
year without recurrence. Patients’ baseline characteristics are detailed in table 1. 
 
The associations between baseline characteristics and both low quality of life (LSS 
<55) prior to treatment and mortality are presented in Table 2. Participants who 
smoked, had nodal involvement, underwent neck dissection and those reporting 
swallowing difficulties were more likely to have low quality of life before treatment.   
 
Age, disease severity measures, pretreatment low quality of life and high 
psychological disability were all strongly associated with mortality, as was reported 
shoulder and arm pain and swallowing difficulty (Table 2). However, the 
association between pretreatment quality of life and mortality decreased 
substantially after adjustment for co-variates, and became statistically insignificant 
(Table 3).   
 
In contrast, the association between low quality of life post treatment and mortality 
remained strong even after adjustment for demographic and disease severity 
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measures (Table 3). The only other post treatment quality of life measure to remain 
significant after adjustment was head and neck pain. 
 
 
Discussion 
KEY FINDINGS 
The results of this prospective study demonstrate a strong independent association 
between long-term survival and quality of life after treatment for head and neck 
cancer. This is the first time this has been reported in the head and neck literature.  
 
Prior to treatment, overall or global QoL was not strongly associated with long-term 
survival once adjustment for disease severity had been performed, supporting the 
findings of the few other substantive studies on this area in the head and neck 
cancer literature (16,17,18). During the pre-treatment phase, classical predictors of 
survival (age, tumour stage and site) were found to be more important in 
determining long-term mortality. This is consistent with existing literature (16,18), 
further supporting the validity of our findings. 
 
COMPARISON WITH OTHER STUDIES 
In contrast to previous studies, which only examined QoL before or just at the start 
of treatment (2-18), we also examined QoL one year after diagnosis. We 
hypothesized that, intuitively, it is more likely that the steady state QoL - after 
patients had adjusted to the impact of their diagnosis and effects of treatment, and 
had mobilised their coping strategies accordingly - that would be the determinant of 
long-term survival (24,25), rather than pre-treatment QoL. This was based on the 
observations that QOL status usually decreases noticeably during and in the period 
immediately after treatment, and that patients return to a steady state QoL around 
one year after diagnosis (26,27). The findings of this study appear to corroborate 
this premise, and to our knowledge, this is the first time this relationship between 
post-treatment QoL and long-term survival has been demonstrated in the HNC 
literature. It would also explain why a strong association between pre-treatment 
overall QoL and long-term survival could not be demonstrated in our and other 
studies (16-18), as the pretreatment QoL may be strongly confounded by disease 
severity and uncertainty regarding treatment. 
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LIMITATIONS OF THE STUDY 
We are aware of potential limitations of this kind of study:  
All cause mortality was used as the end point, as we were unable to always 
accurately define cause of death, because we frequently used death certificates for 
information, with the accompanying unreliability of this source as an indicator of 
true cause of death in cancer patients. In any event, it is our experience that 
patients are interested in their overall survival prognosis, rather than disease 
specific survival.  
As with most studies of HNC, due to the relatively low incidence of the disease and 
the heterogeneity of the tumour sites, there are small numbers of patients in each 
tumour site sub-group. This may lead to analysis bias because significant 
associations may not be detected due to low sample numbers. Furthermore, there 
was incomplete data for all included patients leading to attrition of patients 
available for analysis. Confidence intervals were provided to adjust for this. 
We did not collect data on co-morbidities (apart from smoking and alcohol 
consumption), as at the time of inception of the cohort and at 1 year after 
diagnosis, the idea of 10 year QoL follow-up and the role of co-morbidities as a 
determinant of long-term QoL were not widely contemplated or considered by the 
authors or the literature at that time. Therefore we have not adjusted for co-
morbidities in our study. This raises the possibility that the association between 
QoL and long-term survival may be confounded by co-morbidity and may be in fact 
a reflection of it, as some authors have found co-morbidity to be a significant 
prognostic indicator of survival. On the other hand, there are others, including 
some examining HNC (17), who have found that co-morbidity does not play a role.  
 
We excluded patients with recurrent disease undergoing palliative treatment when 
re-assessing QoL at 1 year. These patients are known to have both a poor quality 
of life and a short survival duration (2,4,5). Since this study was examining long-
term survival, the authors felt that including these patients in the analysis was 
inappropriate as it would bias the results by strengthening the association between 
QoL and survival.  
 
This line of research in other cancers, such breast and lung cancers (10-11) has 
demonstrated some strong associations between pre-treatment overall QoL and 
survival, which is at variance with our findings in HNC. However there have been 
other long-term studies, which have not found this relationship, or only found 
limited associations with single component variables (13-15). The reasons for 
these inconsistencies are unclear, and are likely to be multiple – including 
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methodological differences, small study numbers, differences in tumour types and 
behaviour, and confounding by other factors.  
 
There are also conflicting findings in the literature regarding the role of 
psychological factors, such as depression, in determining survival from cancer. 
Some report that psychosocial complaints are independent prognostic factors of 
survival following cancer (2), including HNC (18). Others (4,13,16), however, have 
not demonstrated such a relationship. This study did not find a strong association 
between psychological distress (as measured by GHQ) and long-term survival. 
Hence, it would seem that the relationship between QoL and survival may be in 
some, possibly large, part independent of psychological state. 
 
CLINICAL RELEVANCE 
Notwithstanding the difficulties with data and analysis, we believe we have 
produced sufficient evidence to warrant further investigation of the association 
between global QoL and survival in HNC patients. Whilst no causative relationship 
can be proven from this study, our findings may mean that interventions to improve 
QoL can potentially improve survival. Elucidating and understanding these 
associations, as well as the prognostic role of co-morbidities, more clearly would be 
important in establishing whether QoL can be manipulated to enhance survival. 
Ultimately, the relationship between QoL and long-term survival will only be 
considered useful if interventions can effect any actual therapeutic or survival 
advantage. 
 
Conclusions 
This study has demonstrated, for the first time, an independent and strong 
association between quality of life after treatment and long-term survival in head 
and neck cancer patients. Whilst a weak association between pre-treatment QoL 
and survival was demonstrated, recognized risk factors (age, disease site and 
extent) were found to be the main prognostic factors in the pre-treatment period. 
The findings suggest potential survival benefits from improvements in QoL. 
However, the observed associations between survival benefit and one year QoL 
may be confounded by co-morbidity, which was not measured, and this deserves 
further investigation. 
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Figure 1.  Kaplan-Meier plot of survival with 95% confidence interval 
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     Table 1: Characteristics of study group at baseline and at 1 year. 
 
Baseline 
n=200 
 Cohort at 1 year  
n=137 
Demographics and co-morbidites   
  Male 152 (76%) 108 (79%) 
  Age 64  11.9 63  11.9 
  Alcohol consumption nearly/every day 67 (34%) 48 (35%) 
  Ever smoked 170 (85%) 117 (85%) 
Disease Status   
  AJCC Stage   
  I 35 (18%) 28 (20%) 
 
 II 30 (15%) 22 (16%) 
  III 45 (23%) 35 (26%) 
  IV 69 (35%) 40 (29%) 
  Nodal involvement 86 (43%) 53 (39%) 
  Tumour Site   
  Supraglottis 29 (15%) 21 (15%) 
  Glottis 47 (24%) 41 (30%) 
  Oro/naso/hypopharyx 64 (32%) 34 (25%) 
  Oral 26 (13%) 19 (14%) 
  Other 34 (17%) 22 (16%) 
  Treatment   
  Surgery 32 (16%) 26 (19%) 
  Radiotherapy 64 (32%) 44 (32%) 
  Surgery & Radiotherapy 81 (41%) 67 (49%) 
  Neck dissection 64 (32%) 51 (37%) 
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Table 2: Association between pre-treatment characteristics, all cause mortality 
               and overall quality of life at baseline (univariate analyses) 
 
 Hazard ratio (95% CI)  
for all cause mortality 
Odds ratio (95% CI)  
for low quality of life 
at baseline 
 HR (95% CI) P value OR (95% CI) P value 
Demographics and co-morbidites     
 Male 0.74 (0.50, 1.08) 0.119 2.0 (0.81, 4.72) 0.137 
 Age  >72 (Highest Quartile) 1.76 (1.23, 2.50) 0.002 0.6 (0.28, 1.42) 0.265 
 Smoker 0.95 (0.58, 1.56) 0.830 4.7 (1.08, 20.7) 0.039 
 Alcohol consumption nearly/every day 1.04 (0.73, 1.48) 0.847 1.1 (0.54, 2.19) 0.803 
Disease status     
 Disease Stage     
  Stage III & IV vs I & II 2.5 (1.66, 3.78) <0.001 2.1 (0.93, 4.53) 0.074 
 Nodal Involvement 2.2 (1.52, 3.05) <0.001 2.2 (1.12, 4.39) 0.023 
 Tumour Site     
  Supraglottis vs glottis 2.5 (1.66, 3.78) 0.001 1.3 (0.44, 4.11) 0.783 
  Oral vs glottis 1.6 (0.82, 3.09) 0.175 1.9 (0.62, 5.67) 0.242 
  Oro/naso/hypopharyx vs glottis 3.0 (1.82, 4.88) <0.001 1.4 (0.56, 3.54) 0.598 
  Other vs glottis 2.5 (1.39, 4.33) 0.002 0.7 (0.22, 2.41) 0.224 
 Treatment     
  Surgery vs surgery & radiotherapy 0.6 (0.35, 1.06) 0.078 0.4 (0.14, 1.39) 0.162 
  
Radiotherapy vs Surgery & 
radiotherapy 
1.0 (0.64, 1.42) 0.814 0.5 (0.24, 1.26) 0.157 
 Neck dissection 1.7 (1.19, 2.51) 0.004 2.5 (1.18, 5.33) 0.017 
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  QoL and disability measures     
 Life satisfaction < 55 (Lowest Quartile) 1.5 (1.02, 2.22) 0.038 … … 
 GHQ >23 (Highest Quartile) 1.6 (1.10, 2.39) 0.015 2.1 (1.00, 4.35) 0.051 
 Head and neck pain  1.6 (1.11, 2.23) 0.012 1.7 (0.88, 3.48) 0.112 
 Shoulder and arm pain 0.9 (0.41, 1.87) 0.122 1.3 (0.34, 5.26) 0.679 
 Cough constantly/most days 1.2 (0.87, 1.74) 0.233 1.6 (0.80, 3.08) 0.185 
 Speaking difficulty 0.9 (0.52, 1.71) 0.842 1.8 (0.64, 5.16) 0.260 
 Swallowing difficulty 2.0 (1.42, 2.92) 0.001 2.3 (1.13, 4.63) 0.022 
 
Key: 
Poor quality of life is indicated by a life satisfaction score < 55.; CI indicates confidence 
interval. 
High psychological distress as indicated by GHQ (general health questionnaire) score >23 
(highest quartile). 
All above are univariate analyses.  
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Table 3: Association between quality of life measures at baseline and at 1 year 
               and mortality unadjusted and adjusted for potential confounders.   
 
 
 Hazard ratio (95% CI) 
for mortality 
Hazard ratio (95% CI) for 
mortality adjusted for 
age, gender, smoking, 
alcohol consumption, 
disease stage, nodal 
involvement and tumour 
site 
 HR (95% CI) P value HR (95% CI) P value 
Quality of life measures at baseline     
Life satisfaction <55 (LQ) 1.7 (1.1, 2.5) 0.010 1.4 (0.9, 2.4) 0.145 
Other quality of life measures†  1.2 (0.8, 1.9) 0.337 1.4 (0.8, 2.4) 0.223 
 
Quality of life measures at 1 year 
    
Life satisfaction <55 (LQ) 3.0 (2.1, 4.2) <0.001 2.5 (1.4, 4.3) 0.001 
General health >23 (HQ) 0.9 (0.5, 1.4) 0.263 1.1 (0.6, 2.1) 0.724 
Head and neck pain  1.9 (1.2, 3.1) 0.008 1.9 (1.1, 3.4) 0.024 
Shoulder and arm pain 1.6 (1.0, 2.6) 0.066 1.5 (0.84, 2.7) 0.166 
Cough constantly/most days 1.4 (0.9, 2.2) 0.133 1.1 (0.6, 1.7) 0.835 
Speaking difficulty 1.1 (0.6, 1.8) 0.780 0.8 (0.5, 1.5) 0.428 
Swallowing difficulty 1.4 (0.9, 2.2) 0.140 1.3 (0.7, 2.2) 0.399 
 
Key 
LQ indicates lower quartile; HQ highest quartile. 
†includes GHQ, head and neck pain, shoulder pain, cough, speaking and swallowing 
difficulties. 
CI indicates confidence interval.  
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Abstract 
Objective: Update a previous review examining associations between psychosocial 
factors and survival in head and neck cancer patients.   
 
Data Sources: Searched Cochrane, Psych info and Embase for the period from 1 
January 1995 to 1 April 2010, as well as personal and article reference lists and 
article archives. 
 
Study Selection: Identified articles assessed by consensus for eligibility using 
following criteria: survival as outcome measure; psychosocial factors as prognostic 
indicators; results specifically for head and neck cancer patients, not including 
oesophageal or thyroid cancer. Seven of 74 articles fulfilled criteria.  
 
Data Extraction: Data abstracted independently by two reviewers using 
predetermined proformas. Quality was also rated using Scottish Intercollegiate 
Guidelines Network 50 tool.  
 
Data Synthesis: At baseline, expression of intense psychosocial complaints, higher 
self-perceived physical ability, self-reported high physical functioning and the Short 
Form-36 physical component score were significantly associated with increased 
survival.  
 
Uncertainty about the diagnosis and treatment was found to be a negative 
prognostic indicator, as was being single, poor cognitive function, baseline fatigue, 
pessimism and alcoholism. 
 
Overall quality of life and head and neck pain, eating score, speech and SF-36 
physical functioning post treatment were found to be significantly associated with 
survival. However, overall quality of life and depression at the time of diagnosis 
were not. 
 
Conclusions. There appears to be some association between selected 
psychosocial factors and long term survival from head and neck cancer. However 
this relationship is currently neither strong nor proven, requiring examination by 
multi centred trials with standardisation of research definitions and methodologies, 
and examination of post treatment psychosocial factors. 
 
Association of psychosocial factors and survival 
 
Introduction 
The link between the psyche and cancer has intrigued researchers throughout the 
ages. Hypocrites, two thousand years ago, noted that women with excess black 
bile were more melancholic and were more prone to cancer than those who had 
excess blood and were more sanguine (1) and Galen in 200AD stated in his 
Tumoribus that cancer was more common in melancholic women (2). Naturally, 
these comments were not the result of scientific experiments. It was not until 1893 
that the first scientific study on the subject was published by Snow. He reported a 
statistical analysis of the association between psychological factors and cancer in 
250 patients, and concluded that stressful life events were associated with the 
development of cancer in the majority of patients (3).   
 
In the second half of 20th century, there was a considerable increase in interest in 
the field of cancer psychology, with a consequent increase in research in the field. 
This activity was to mark the start of psycho-oncology as a discipline (4). These 
studies from the 1950s and 1960s showed that emotional expression was 
associated with survival (5-7). Furthermore, patients with poor social support or 
loss of social support, for example through death of a spouse, were also shown to 
have a lower survival rate from cancer.   
 
In the latter part of the century, experiments were performed to examine the 
possible mechanisms that may be involved in this association – especially 
concentrating on the role of corticosteroid levels and immune factors (8 -9). As a 
result, several models of the interaction of psychological, social factors and cancer 
appeared, some of which also included biological mechanisms. These included the 
Andersen Biobehavioural Model of Cancer Stress and Disease Course (9), the Van 
de Borne and Pruyn Coping model (10), The Dirksen Well Being model (11) and 
Thomas’ model of distress (12). The Andersen model is especially interesting as it 
incorporates interactions between psychological behaviour and biological factors to 
explain their effects on disease course and progression (9).   
 
The importance of establishing an association between psychosocial factors and 
long-term survival lies in the fact that psychosocial interventions have recently 
been found to improve quality of life and the psychological status of head and neck 
cancer patients (13,14). If there is an identifiable relationship between psychosocial 
factors and long term survival, then improving patients' psychosocial state could 
improve the long term survival in susceptible patients.   
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In 1998, one of the authors (MdB) published a review of the available literature to 
1995, on the association of psychosocial factors and survival in cancer (15). He 
concluded that there were often contradictory findings in the literature regarding the 
associations between different psychosocial factors and long-term survival in 
cancer. Some of the problems identified were: the multitude of definitions and 
psychosocial measures used, different methodologies, small populations under 
study with mixed cancer sites, different follow up durations and different analysis 
strategies. Despite the heterogeneous nature of the research, it is noteworthy that 
till 1995 there had been no studies examining the relationship between 
psychosocial factors and survival from head and neck cancer.  
 
The aim of the current review is to update the previous review (15) by examining 
subsequent research that has addressed the possible association between 
psychosocial factors and survival in head and neck cancer patients.   
 
Methods 
An electronic literature search of the Cochrane, Psych info and Embase databases 
was performed for the period from 1 January 1995 to 1 April 2010. The search 
strategy began with a search of the terms in Table 1 as key words, and/or words in 
the abstract or title. These were then cross-referenced with the following terms: 
head and neck, cancer, neoplasm, larynx, pharynx, oral, upper aero digestive tract, 
survival, mortality and recurrence.  A search of personal reference lists and article 
archives was also performed, as was an inspection of the reference lists from the 
articles identified by the literature review.   
 
The identified articles were then assessed for eligibility according to the following 
criteria:  
1. Survival as the outcome measure 
2. Psychosocial factors as prognostic indicators 
3. Results reported specifically for head and neck cancer patients  
4. Exclude studies that report only on oesophageal or thyroid cancer  
 
The quality of the papers was also rated, using the Scottish Intercollegiate 
Guidelines Network (SIGN) 50 tool, which is a validated instrument used to assess 
quality of studies (particularly their internal validity) in a structured manner 
according to pre-determined criteria – examining aims, selection of subjects, 
assessment statistical analysis and confounding (16). The instrument results in a 
rating of overall quality that varies from ++ “high quality” that fulfils most (i.e. more 
than 50%) of the quality criteria, to + “average quality” that fulfils some (i.e. 20-
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50%) of the criteria, or – “poor” that fulfils few or none (i.e. less than 20%) of the 
criteria.  
 
 
Results 
There were 76 articles initially identified that related to head and neck cancer. The 
psychosocial factors that were reported by the various studies, and the instruments 
used are listed in table two. Only 13 studies fulfilled the eligibility criteria and these 
studies, including quality assessment, are summarised in table three.  
 
BASELINE ASSESSMENT 
At baseline, expression of intense psychosocial complaints (17), physical self-
efficacy (that is, higher self-perceived physical abilities) (17), self-reported high 
physical functioning (24) and the Short Form-36 physical component score (47) 
were associated with increased survival.  
 
Uncertainty about the diagnosis and treatment was found to be a negative 
prognostic indicator (17), as was being single (17, 18, 43), poor cognitive function 
(19), baseline fatigue (20, 24), pessimism (45) and alcoholism (21).  
 
Overall, or global, quality of life at the time of diagnosis was not associated with 
survival in any of the studies. Depression at presentation was not associated with 
survival except in Aarsted et al’s small study (23), and then only through an 
association with stage (i.e. not an independent risk factor).  
 
ASSESSMENT AFTER TREATMENT 
Overall quality of life - as represented by Life Satisfaction Score - was significantly 
and independently associated with subsequent survival (22) in one large 10-year 
study.  Global quality of life – by EORTC - at 6 months post-treatment and a 
deterioration of quality of life between 6 months and baseline were also found to be 
significant predictors of long-term survival by another study (43). A smaller, 5-year 
study mentioned briefly that they did not appear to find an association. Its results 
for this particular aspect were excluded however due to insufficient information 
being provided and inadequate methodology used to determine the association 
(24).   
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Other specific symptoms following treatment were also found to be associated with 
survival. These included pain (22,44), eating (44), speech (44) and physical 
functioning (44)   
 
 
Discussion 
KEY FINDINGS 
There are several psychosocial factors that may be associated with long-term 
survival such as post-treatment global quality of life, physical self-efficacy, 
expression of complaints and emotions, cognitive function, marital status and 
alcoholism.  Some of these factors may be confounded by – or surrogates for - 
other factors or causes. Indeed, the findings are inconsistent and at times 
contradictory. This lack of consistency may reflect an absence of an actual 
association between psychosocial factors and quality of life. However it may also 
be a reflection of several methodological shortcomings. 
 
One important shortcoming of most studies is that they are single centre 
experiences, many with relatively small sample sizes and of cancers from several 
head and neck sites. These factors will impact on the power and sensitivity of such 
studies. Another contributing factor may be that definitions of psychosocial factors 
and the methods for their measurement are far from standardised. There is also a 
lack of homogeneity in outcomes reporting. Even when the instruments are the 
same, the studies have different methodological designs - for example 
retrospective versus prospective cohorts versus case control studies (Table 3). 
Indeed, whilst using the same instrument (the EORTC QLQ C30) four studies each 
found a different psychosocial factor to be significantly associated with survival 
(19,20,23,24).  
 
Considerable effort needs to be directed toward obtaining consensus and 
achieving standardisation of definitions, designs and methodologies, preferably in 
the context of multi centre, and possibly international, trials. When considering 
such studies, the role of culture as an important confounding factor in quality of life 
assessments would need to be taken into account (25). 
 
Consideration should be given to the timing of the assessment and measurement 
of the psychosocial factors under study.  It would appear that most studies examine 
the association of baseline psychosocial factors with long-term survival.  Indeed 
there may be personality traits that are best measured, or identified, at diagnosis, 
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before treatment. This may allow psychosocial intervention to start at the same 
time as the medical treatment. Fawzy at al (26) concludes in a review that  ‘early 
stage interventions that encourage active behavioural coping and active cognitive 
coping rather than avoidance or passive acceptance of the illness can attenuate 
distress, decrease the amount of psychosocial adjustment to the illness needed, 
improve quality of life, and may also be associated with longer survival time’. 
   
However it has been clearly shown that patients’ quality of life varies during the 
course of the disease. Several studies have demonstrated that patients’ quality of 
life drops significantly during treatment, and then begins to rise again, about 3-6 
months after diagnosis. By the end of the first year, patient’s quality of life usually 
has returned to its pre-treatment levels (24, 25, 27-29). Most studies indicate that 
quality of life then reaches a plateau for at least the next two years. This variation 
during the course of the disease may also apply to some of the other psychosocial 
factors such as anxiety and psychological distress (24), although other factors (e.g. 
smoking) may not change at all. Late deterioration in quality of life and 
psychological distress has been described (27), but the point at which such decline 
begins is not clear. 
 
Intuitively, it seems to us more likely that the steady-state psychosocial status after 
treatment would be a more significant determinant of long-term survival than the 
psychosocial status before treatment. A few studies have now examined post 
treatment factors in detail (22,43,44), and there was indeed a strong correlation 
between post-treatment quality of life and long-term survival. Therefore, we would 
suggest that future studies should also examine psychosocial factors after 
treatment at the point when a steady state has been achieved. The evidence is that 
patients' quality of life begins to plateau at one year post diagnosis (24,27-29), and 
this may be a good time-point to use.  
 
Certainly, there is sufficient data emerging to support future research on the 
potential role of psychosocial factors in head and neck cancer prognosis, including 
examining existing psychosocial parameters (such as coping strategies) that have 
not generally been captured in studies so far. Clearly, more work needs to be done 
in this area. 
 
Conclusions 
Long-term survival from head and neck cancer appears to be related, both at 
baseline and after treatment, to some psychosocial factors, such as cognitive 
function, fatigue, self-efficacy and expressed uncertainty. However this relationship 
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is not currently clear in the literature. There is significant variability and sometimes 
contradiction in the reported result, and this may suggest the lack of any real 
association. It may also reflect the considerable heterogeneity in definitions, 
methodologies, and designs, and sizes of the studies.  Standardisation of these in 
the context of multi centred trials and the examination of post treatment 
psychosocial factors should be undertaken in an effort to elucidate this relationship 
further.   
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Table 1: Psychosocial terms and definitions used in electronic search strategy 
 
anxiety, coping strategy, depression, dispositional optimism, emotional support, 
employment, extroversion, fighting spirit, hopelessness, hostility, locus of control, 
loss of control, marital status, negative feelings, positive life evaluation, psycho 
social well being, self esteem, social involvement, social network, social support, 
social ties, trait anxiety, quality of life  
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      Table 2: Psycho-social factors examined in the literature with scales  
                     used for assessment. 
Measure Instrument(s) Refs that 
used it 
QOL measures:   
Global or overall QOL  EORTC QLQ C30 37,43 
 LSS, AQLQ 22,27 
 SF-36 44 
Post-treatment quality of life  LSS, AQLQ 22,37 
General psycho-social well-being  RSCL 32 
Physical status indicators:   
Head and neck specific complaints  EORTC QLQ C30 Several 
 Bespoke scales Several 
 EORTC HN35 37 
 HNQOL 44 
 AQLQ 22,27 
 FACT HN 46 
Physical self efficacy  Ryckman scale 34 
Cognitive function  EORTC QLQ C30 37 
Fatigue  EORTC QLQ C30 37 
Psychological disability measures:   
Depression  CES-D  30,38 
 Beck depression inventory  39 
Anxiety  STAI 40 
Psychological distress  GHQ  22,27 
Personality trait indicators:   
Coping  LOC ⁄MHLOC  32,35,36 
 van de Borne scale LOC 33 
 Cancer locus of control  35 
 Wallston and Wallston  36 
Self esteem  CPI  31 
Uncertainty  Bespoke  31 
Dispositional optimism  Bespoke  31,45 
Humour  Svebak humor  41 
Neuroticism  EPI  42 
Other factors:   
Marital status  Several  
Alcoholism  MAST  21 
 
Key : AQLQ, Auckland Quality of Life Questionnaire; CES-D, Centre for Epidemiological Studies-
depression; CPI, California Psychological Inventory; EORTC HN 35, EORTC head and neck specific 
questionnaire; EORTC QLQ C30, European Organisation of Radiation and Treatment of Cancer QLQ 
C30 general questionnaire; EPI, Eysenck personality inventory; GHQ, General Health Questionnaire; 
LOC, locus of control; LSS, Life satisfaction score; MAST, Michigan alcoholism screening test; MHLOC, 
Multidimensional health locus of control; QLQ, quality of life questionnaire; QOL, quality of life; RSCL, 
Rotterdam symptom check list; STAI, Spielberger trait anxiety inventory; HNQOL, Head neck Quality of 
Life questionnaire; SF-36, short form quality of life 36 questionnaire;  FACT HN,  Functional 
Assessment of Cancer Therapy Head and Neck. 
 Table 3: Summary of studies showing positive association between psychosocial factors and survival of head and neck cancer patients. 
Author Quality Sample size 
(exclusions) 
Study design  Follow up Statistical tests Psycho-social Factor(s) 
HR/RR mortality (CI) 
Aarstad et al 2005, 
Bergen (23) 
+ 78 (51) 
Only 27 
analysed 
Case control;  72 mth Pearsons rho, 
Cox regression, 
ANOVA 
Anxiety and depression - NS 
Svebak humour NS 
Balkrishna et al 
2000  Mumbai (18) 
- 6311 (15% 
missing data) 
Retrospective  60mth  Single status HR 1.2 (1.0-1.4)  
Religion - Christian HR 1.3 
(1.1 – 1.5) 
De Boer et al, 1998, 
Rotterdam ( 17) 
++ 133 (58) Prospective  72 mth Kaplan-Meier / log 
rank tests. 
 
High intensity of complaints- 
improved survival 
Perceived self –efficacy- 
improved survival 
Uncertainty  - decreased 
survival 
De Graeff, et al 
2001, Utrecht (19) 
++ 208 (58 
refused) 
Prospective  62 mth Cox regression, 
Kaplan-Meier, log 
rank 
Poor cognitive function on 
EORTC– RR 1.85 (1.06-3.33). 
Unmarried RR 1.82 (1.03-
3.23) 
Deleyiannis  et al 
1996 Seattle (21) 
++ 649 (159)  
 
Retrospective  84mth Cox proportional 
hazards 
Alcoholism HR 2.06 (1.43-
2.98) 
History of alcohol related 
health problems HR 2.76 
(1.69 – 4.49) 
Fang et al  
2004, Taiwan (20) 
+ 102 (N/A) Prospective 36mth Cox proportional 
hazards  
Baseline fatigue on EORTC – 
HR 1.0174 (1.0081-1.027) 
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2006, Auckland 
(22) 
++ 200 (4) 
[130 at 12 
months] 
Prospective 120mth Cox proportional 
hazards ratio 
QoL at diagnosis NS. 
QoL 1 year after diagnosis, 
poor life satisfaction score 
<55) - HR 2.5 (95% CI 1.4, 
4.3) 
Head and neck pain – HR 1.9 
(1.1, 3.4) 
Nordgren et al 
2006,(24) 
Sweden/Norway 
+ 89 (N/A) 
[65 at 12 
months] 
Prospective  60 mth Cox proportional 
hazards 
Physical function scale on 
EORTC - HR 0.98  (0.97-
0.99), 
advanced stage - HR 5.59 
(1.68-18.6)  
Similar global QoL at 
12months in survivors over 5 
years and those who died 
between 1-5 years.  
Allison PJ 2003 
(45), France 
++ 101(1) [51 at 1 
year] 
Prospective 12 mnth odds ratio Baseline: Dispositional 
optimism - pessimistic 
subjects (OR 1.12; 95% CI 
1.01 -1.24) living alone (OR, 
4.14; 95% CI 1.21 - 14.17)  
Siddiqui F 2008 
(46), USA 
+ 1093 (417) Prospective 49mnth ??? Baseline: no association of 
FACT HN score with overall 
survival but associated with 
locoregional control  
Grignon, 2007, 
(47), USA 
+ 919 (415) Prospective 60mnth Cox proportional 
hazards 
Baseline: SF-36 physical 
component score predicts OS 
(risk ratio 0.97) and DSS 
(0.98). Comorbidity also 
predicts OS and DSS. Mental 
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component o SF-36 does not. 
Karvonen-Gutierrez 
,2008 (44), 
Michigan , USA 
+ 973 (588) 
post-treatment 
Retrospective, 
cross-sectional  
61 mnth Cox proportional 
hazards ratio 
Post treatment  (median 
4mnth): SF-36 physical 
component score (0.86, 95CI 
0.80 to 0.93); HRQOL pain 
(0.92, 95CI 0.87 to 0.98), 
eating (0.94, 95CI 0.89 to 
0.99), speech (0.92, 95 CI 
0.87 to 0.96),  
Married (0.68, 95 CI 0.50 to 
0.92) 
Oskam et al, 2010 
(43), Netherlands 
++ 80 (12) [55 at 
6mnth] 
Prospective 58mnth Cox regression 
relative risk 
Baseline: partner (3.10; CI 
1.36-7.06) predicted DSS 
6 months: EORTC global QoL 
(0.96, CI 0.94-0.98) and 
deterioration of global QoL 
(5.08, CI 2.3-14.6) predicted 
both DSS and OS. 
Key: 
EORTC: EORTC Quality of life questionnaire , CES-D : , HR : hazards ratio for mortality, RR: relative risk of mortality, N/A : not available, , mth: 
months; NS – not significant , QoL -quality of life, DSS – disease specific survival 
HNQOL – Head neck Quality of Life questionnaire, SF-36 – short form quality of life 36 questionnaire FACT HN – Functional Assessment of 
Cancer Therapy Head and Neck 
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Abstract 
Aim: to quantify and qualify the use of QoL measures by head and neck cancer 
(HNC) clinicians and to identify any impediments to their use. 
 
Methods: questionnaire survey of members of Australia and New Zealand HN 
society 
 
Results:  128 of 187 (68.5%) responded. Only 43 (34%) had ever used a QLQ, and 
only 17 (13%) were currently using one. Impediments to use included too time 
consuming and no proven benefit for clinical management. Nevertheless 113 
(88%) indicated willingness to use a minimum core QoL questionnaire – for routine 
clinical use and for research – but indicated a preference for short (10-15 
questions), quick (less than 10 minutes) questionnaires.  
 
Conclusions: most HNC clinicians did not use a QoL measure routinely, with 
impediments to routine use being mainly clinician based. Most respondents would 
use a minimum core QL measure, especially if it were a short quick consensus 
questionnaire. 
 
Introduction 
Quality of life (QoL) measurement is now widely considered to be integral to best 
patient care (1). Indeed the most recent BAO HNS consensus document states 
that QoL measures are an essential outcome measure of HN surgery and should 
be included in the minimum HN dataset (2). Furthermore QoL measures have been 
included in the BAHNO advisory dataset and the British National HN cancer 
dataset (3). Despite these recommendations, a recent survey of head and neck 
cancer clinicians in the U.K. indicated that most were not engaged in any QoL data 
accrual (4).   
 
This study sought to determine whether the UK experience was reflected 
elsewhere and to enquire further regarding reasons for clinicians’ choices 
regarding QoL data. To achieve this, head and neck oncologic physicians and 
surgeons in Australia and New Zealand were surveyed, specifically to quantify and 
qualify the use of QoL measures and identify any impediments to the use of such 
measures. 
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Methods 
The Australian and New Zealand Head and Neck Society (ANZHNS) consists of 
187 professionals involved in the care of head and neck cancer in Australia and 
New Zealand. Most members are consultant medical practitioners, with the 
following backgrounds: otorhinolaryngology (33%), plastic surgery (20%), radiation 
oncology (21%), maxillofacial surgery (11%), head and neck surgery (7%), medical 
oncology (2%), general surgery (1%), and others (1%). Their principal objectives 
are ‘to promote the practice of head and neck oncology, to educate medical 
colleagues and the public about our specialty, to foster research and to seek 
optimal treatment outcomes for our patients’ (5). 
 
All members of the ANZHNS were surveyed using an anonymised postal 
questionnaire (appendix A) enquiring about their use of QoL questionnaires (QLQ), 
reasons for this and their criteria for an acceptable minimum consensus QLQ. Non 
–responders were sent a follow-up survey.   
 
 
Results 
Of the 187 members, 128 (68.5%) responded. Of these, otorhinolaryngologists 
comprised 47 (37%), radiation oncologists 30 (23%), plastic surgeons 26 (20%), 
maxillofacial surgeons 9 (7%), head and neck/general surgeons 9 (7%), medical 
oncologists 4 (3%) and speech pathologists3(3%). Most (122 - 95%) were 
consultants. Figure 1 shows the respondents as a proportion of members by 
specialty. 
 
Of the 128 respondents, only 43 (34%) had ever used a QLQ, and only 17 (13%) 
were currently using one, of whom only 2 (1.5%) were using it in routine clinical 
practice, either as an outcome measure or for follow-up. The remainder (i.e. 11.5% 
of all respondents) were using QLQ as part of QL research or as part of a clinical 
trial. Radiation (47%) and medical oncologists (50%) were proportionately more 
likely to have used a QLQ than surgeons [maxillofacial surgeons (44%), 
otolaryngologists (36%), general surgeons (22%)], and almost exclusively used it 
for research purposes. Only 1 (4%) of 26 plastic surgeon respondents had used a 
QLQ. 
 
Of those 27 respondents who had ceased using a QLQ, almost half (13, or 48%) 
stopped because they thought it did not add value to clinical management or that it 
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was too intrusive in a clinical setting. Other reasons for stopping included: - clinical 
trial ending (5; 19%); patients did not want it (2; 7%); questionnaires did not fulfil 
their needs (4; 15%); and did not know what to do with the information (3; 11%). 
 
When asked about the desirability of a short screening questionnaire for identifying 
patient complaints, 85 (66%) indicated somewhat or extremely desirable, with 31 
(24%) indicating it would be undesirable, with no differences between oncologists 
and surgeons. 
 
Most [113 (88%)] of the 128 respondents indicated that they would use a 
consensus minimum head and neck cancer QLQ. Of those, 46 (40%) would use it 
for clinical purposes only, such as routine follow-up, screening for problems and as 
a clinical outcome measure, whilst 24 (21%) would use it for research purposes 
only, and 43 (38%) would use it for both (figure 2). Over 90% indicated that a 
questionnaire with up to 10 -15 questions taking 10 minutes to complete would be 
an acceptable format. 
 
Of the 15 (12%) respondents who would not consider using a core questionnaire, 
only 3 thought that patients did not like questionnaires. The remainder indicated 
physician based reasons, such as not adding value to patient management, too 
time consuming in a clinic or not knowing what to do with the information (figure 3).  
 
 
Discussion 
KEY FINDINGS 
Although research interest in HN QoL is at its highest (1), and professional and 
governmental bodies have stipulated the need for routine QoL measurement (2-4), 
the vast majority of head and neck clinicians in our study were not measuring QL 
as a clinical outcome measure. Only a third of our respondents had ever used 
QLQ, and only a small proportion of these were currently using one, mainly as part 
of research or a clinical trial. Oncologists were more likely to have used a QLQ 
than surgeons, primarily because of their increased involvement in clinical trials. 
Interestingly, both those who had stopped using QLQ and those who do not want 
to use QLQ at all did so because of physician related reasons, mainly because it 
was too time consuming, they did not find QLQ of any benefit to patient care, or 
that the QLQs did not fulfil the clinicians’ needs.  
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COMPARISON WITH OTHER STUDIES 
These findings are very similar to those of a UK survey carried out on British head 
and neck oncologists (4). That survey had also found that only 29% of respondents 
had used QLQ, and that the main reasons for not using them were ‘lack of 
resource and proven value’. Furthermore, respondents in both studies indicated 
that the main problem with QLQ was that they were too time consuming in a clinic 
setting. 
 
Yet most clinicians in our survey indicated that they would consider using a 
consensus minimum dataset QLQ, with the great majority indicating that they 
would use it in routine clinical practice, either as an outcomes measure or for 
problem identification. However the respondents also indicated that the QLQ 
should be short, taking upto 10 minutes to complete. Furthermore, two thirds 
indicated their desire for a short questionnaire to screen for patient complaints and 
problems, such as pain, physical and psychological dysfunction. 
 
LIMITATIONS OF STUDY 
There are limitations in our study. The main one is that the response rate, while 
good for postal questionnaires, is still only modest, and will carry response bias. 
Also, the membership of ANZHNS is not a complete register of professionals 
involved in the management of head and neck cancer in Australia and New 
Zealand, which may lead to sample bias. Furthermore, the surgical respondents’ 
backgrounds are biased towards otolaryngology. Interestingly the UK study was 
sourced from a maxillofacial unit, and respondents’ backgrounds were biased 
towards maxillofacial surgery, and this may reflect a tendency for members to 
respond better when the authors are from their own specialty. However, it is 
reassuring that the findings of both studies are very similar despite the possible 
biases, and the different geographies and healthcare systems. 
 
CLINICAL RELEVANCE 
There appears to be a significant gap between the current status of QoL 
measurement in clinical practice and the ideal, or even what the clinicians 
themselves aspire to. This gap would seem to exist because current QLQs do not 
appear to address the needs of the head and neck clinician, who would like a short 
consensus QLQ, and which ideally could also be used to assist patient 
management. Further assessment of current QLQs is needed to identify which of 
these would best fulfil these criteria, and whether modification of existing 
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questionnaires is required to achieve these aims. It is also important that the 
assessment ensures that the selected QLQ also fulfils the needs of the patients. 
Finally, better funding and the utilisation of data managers, who would be 
responsible for the distribution, collection and analysis of QLQ in the clinic, may 
address some of the resource issues, and make routine collection of QL data more 
feasible in clinical practice. 
 
Conclusions 
Most head and neck clinicians do not currently collect quality of life data, mainly 
due to time and resource constraints, or because these questionnaires are not 
perceived to have relevance to patient management. However, most clinicians 
surveyed indicated a readiness to use a short consensus QLQ questionnaire for 
routine clinical practice and for research, if that was available. Therefore, further 
assessment and modification of existing questionnaires is required to satisfy these 
needs, and encourage the measurement of QL outcomes in clinical practice.   
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Figure 1:  Respondents as a proportion of members of ANZHNS by specialty. 
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Figure 2:     Reasons for use of a consensus minimum HNC QLQ 
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Figure 3: Reasons for not using a consensus QLQ 
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Appendix A 
 
The Australian and New Zealand Head and Neck Society 
 
Survey on the use of Head and neck cancer Quality of life Questionnaires 
 
 
We would be grateful if you would fill out this questionnaire, and fax it back to us on 
(+64) 9 631 0770 
It will take less than 5 minutes to complete 
 
 
1.   Which speciality do you belong to? 
i.Maxillofacial   iv.General surgery 
ii. ORL.   v. medical oncology 
III Plastics   vi. Radiation oncology 
vii. Other: please state………………….. 
 
2.   What is your grade? 
i. Consultant or equivalent     
ii. Registrar or trainee       
iii. Non-medical ….. 
 
3. Have you ever used a head and neck Quality of Life questionnaire(HNQLQ): 
a. Yes      
b. No – then please go to question 7  
 
4. Do you still use a HNQLQ? 
a. Yes  
b. No –  then please go to question 6 
 
5. What do you use the HNQLQ for? (you may mark more than one choice) 
a. routine clinical follow-up of patients 
b. routine screening of patients for problems eg pain, psychosocial 
c. routine outcome measure of treatment in clinical practice 
d. Quality of life (QoL) research 
e. Outcome measure as part of a clinical trial 
f. Other: please state…………….. 
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Now please go to question 7 
 
6. Why did you stop using a HNQLQ? (you may mark more than one choice) 
a. does not add value to clinical management of patient 
b. too time consuming or intrusive in a clinic setting 
c. not wanted by patients  
d. current questionnaires do not fulfil my needs 
e. did not know what to do with the information 
f. other: please state………………. 
 
7. How desirable do you think it is to have a short screening questionnaire for 
identifying problems eg pain, psychosocial, physical dysfunction? 
a. extremely undesirable 
b. somewhat undesirable 
c. indifferent – neither desirable or undesirable 
d. somewhat desirable 
e. extremely desirable 
 
8. Would you consider using a consensus core (minimum) head and neck cancer 
quality of life questionnaire? (you may mark more than one choice) 
a. No – please go to question 10 
b. Yes – for routine clinical follow-up of patients 
c. Yes – for routine screening of patients for problems eg pain, psychosocial 
d. Yes – for routine outcome measure of treatment in clinical practice 
e. Yes – for quality of life (QoL) research 
f. Yes – for outcome measure as part of RCT  
g. Yes – other: please state………………. 
 
9. Which of the following would be acceptable to you for a consensus core 
questionnaire,: 
a. Time required to complete questionnaire (please select only one choice) 
i. <1 min   ii. <5 mins   iii.6-10 mins   iv.11-15 mins   v. 16-20   vi.>20 min 
vii. Duration does not matter   viii. Other: please state………  
 
b. number of questions included in questionnaire (please select only one 
choice): 
i. <5 questions  ii. 5-10   iii. 11-15   iv. 16-20   v. 21-25   vi. >25 questions 
vii. number of questions does not matter   viii. Other: please state……… 
 
 119 
Chapter 6 
 120
NOW Please go to comments section below 
 
10. Why would you NOT use a consensus core questionnaire? (you may mark 
more than one choice) 
a. questionnaires do not add value to clinical management 
b. too time consuming in a clinic 
c. patients do not like it 
d. I already use a questionnaire that I am happy with 
e. I would  not know what to do with the information 
f. other: please state……………… 
 
Comments section: 
If you have any comments or suggestions, we would be grateful if you would 
include them in the space below 
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Abstract 
Objectives: 
1. Evaluate head and neck cancer (HNC) patients’ perspectives regarding the 
usefulness of quality of life questionnaires (QLQ) in communicating their health 
problems to clinicians  
2.  Identify the QLQ that HNC patients find most useful.  
 
Design: randomized questionnaire study. Patients completed all four validated 
HNC QLQs – EORTC , FACT HN35, University of Washington QLQ, Auckland 
QLQ. Order of questionnaire presentation was randomized to counterbalance for 
order effects 
 
Setting: tertiary referral HNC centre, Auckland, New Zealand 
 
Participants: 80 patients diagnosed and treated for HNC. Exclusion criteria: 
blindness, learning difficulties or inability to understand or read English.  
 
Main outcome measures: patient ratings of perceived usefulness and preferences 
of studied questionnaires . 
 
Results: Patients reported high relevance to their problems and high ease of 
understanding of all questionnaires, with FACT scoring highest (79% and 89% 
respectively). 58% participants (67% respondents) would like to complete a 
questionnaire in clinic, as it would help them describe their health problems to their 
doctors; 28% of participants did not. Almost half preferred a particular QLQ, FACT 
being most preferred. Length of questionnaire did not affect reported usefulness, 
but most would prefer a short questionnaire (<20 items). 
 
Conclusions: Patients report that HNC QLQs effectively describe their health 
concerns. Most are in favour of completing QLQs in clinic, as an aid for describing 
health problems to clinicians. There appears to be a difference between clinicians 
and patients regarding the perceived usefulness of QLQs in the clinic setting, which 
needs to be highlighted to clinicians. 
 
Introduction 
Routine measurement of quality of life in head and neck cancer practice has been 
strongly recommended by several professional bodies (1). There are several 
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extensively-validated quality of life questionnaires currently available for this 
purpose (2). Furthermore most head and neck cancer clinicians report being in 
favour of health-related quality of life assessment and questionnaires in the clinic 
(3,4).  
 
Despite this, less than a third of  head and neck cancer clinicians have carried out 
quality of life assessments (usually in a research setting) (3). The main 
impediments are reported to be a combination of resource limitations, confusion 
regarding which questionnaire to use and a perceived lack of proven clinical 
usefulness (no impact on patient care) (3,4).   
 
One clinically relevant use of quality of life questionnaires may be as a 
communication aid for patients to describe their health problems to their clinicians. 
Use of quality of life measurement in a clinical oncological setting has been shown 
to improve patient - clinician communication and is associated with an improved 
quality of life and emotional functioning of patients (5). Detmar et al also concluded 
in another randomised trial that use of quality of life questionnaires in routine 
clinical oncological use facilitated patient – clinician communication, and improved 
clinician awareness of their patients’ quality of life issues (6). The same was found 
by Taenzer et al (7). No such work has been done in head and neck cancer to 
date. 
 
It should also be noted that the available validated quality of life questionnaires 
correlate moderately with each other (2), and therefore probably measure similar 
aspects of quality of life. However no assessment or comparison of acceptability of 
different head and neck cancer quality of life questionnaires for use in this setting 
has been attempted. This poses a problem when deciding which questionnaire to 
use in the clinical setting. For example, which questionnaire to use for oral versus 
laryngeal patients or for patients with early disease versus advanced disease. 
 
The aims of this study were: 
1. To examine patient perspectives regarding the usefulness of head and neck 
cancer quality of life questionnaires in communicating their health problems to 
clinicians, 
2. To identify patient reported characteristics of an “ideal” questionnaire for this 
purpose, 
3. To identify which of four validated, widely used head and neck cancer quality of 
life questionnaires patients most prefer to use for this purpose. 
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Methods 
Patients 
Consecutive new and follow-up patients attending the head and neck clinic at the 
Auckland Regional Head and Neck cancer unit were recruited, after informed 
consent, to complete the study survey. The exclusion criteria were inability to read 
or understand English, blindness and learning disability. In total, 80 patients were 
approached to participate: 76 consented, but two subsequently withdrew because 
they felt too unwell to complete the long questionnaire. Of the four patients who 
refused to participate, three declined due to lack of time to complete the 
questionnaire, and one because he was unwell. 
 
Ethical considerations 
Approval was obtained from the local ethics committee as part of a programme of 
quality of life studies, and patients were consented using a customised patient 
information leaflet and consent form by the clinic nurse. 
 
Quality of life questionnaires 
All patients were asked to complete the study survey. This consisted of  the  four 
commonly used, validated, patient–reported quality of life questionnaires: The 
University of Washington quality of life questionnaire v3 (12 questions  and a free 
text area), the FACT Head and neck questionnaire v4 ( 38 questions ), the EORTC 
HN35 questionnaire (34 questions), and the Auckland Quality of Life Questionnaire 
(41 questions). 
 
Value of completion of a quality of life questionnaire 
After each questionnaire, there were four questions enquiring about its 
acceptability and usefulness to the participant (appendix S1).  
 
Comparison between quality of life questionnaires 
At the end of the survey, there were eight questions asking participants to compare 
all four questionnaires, and to rank the questionnaires in terms of most and least 
useful, as well as enquiring about the characteristics of the ideal questionnaire from 
the point of view of the patient (appendix S2).  
  
In order to adjust for the effects of fatigue and /or boredom, due to the large 
number of questions and their somewhat repetitive nature, patients were 
randomised (using a computer generated model) to complete one of four versions 
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of the study survey, in which the quality of life questionnaires were presented in 
different order (see Table 1). Neither investigators nor participants knew or could 
influence the version that any participant received. Subjects could request 
assistance in completing the questionnaire from a clinic nurse who had been 
trained in administering them. 
 
The study survey was piloted on a group of 10 patients and their comments were 
used to amend the final versions as necessary. 
 
Analysis 
Data was input into an excel database, and data were verified by a second person 
then analysed using SAS system. The chi squared test was applied to determine 
statistically significant differences (set at p < 0.05) between different questionnaires 
and also between randomisation arms.  
 
In the ideal characteristics section of the results, the response rates to each of the 
4 questions varied considerably with the potential for bias occurring as discussed 
subsequently in the section on Limitations of the study. Missing data can be 
reported in several ways; either excluded from the analysis or included in the 
analysis as the best and worst case scenarios with a range of values. We have 
elected to perform the latter as it gives a more accurate representation of the 
possible ranges. Routine measurement of quality of life in head and neck cancer 
practice has been done. 
 
 
Results 
Study population  
Patients were predominantly male (68 %), with a mean age of 65 years. Over 80% 
had squamous carcinomas, with the most common site being oral cancer, and with 
a predominance of advanced disease. Over half the patients had been previously 
treated by surgery and/ or radiotherapy and occasionally chemotherapy (see table 
1). The mean duration since treatment for the follow-up patients was 21 months 
(range 1- 120 months). As noted earlier, three patients refused participation due to 
lack of time and one because they were too ill. Two patients withdrew after consent 
due to being too ill.   
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Characteristics of Questionnaires under study 
There was no significant difference between the quality of life questionnaires in 
respect of ease of comprehension, perceived length of questionnaire, relevance, or 
preference, but the following specific features and trends for the various 
instruments were observed: 
 
Ease of comprehension & questionnaire length 
Patients reported a high and similar ease of understanding for each of the 
questionnaires, with the FACT scoring highest (89% respondents) (table 2 and 
figure 1). A small proportion (10-17%) of patients found questionnaires too long 
irrespective of the actual number of questions. 
 
Relevance to health problems and fulfilment of needs 
Patients reported a high relevance of all questionnaires to their problems, with 
FACT again being most relevant (74% of respondents) (table 2 and figure 1). Most 
patients felt that the questionnaires helped them to describe their problems to their 
doctors, with FACT again being reported as the most useful in that regard.  
 
Approximately a third of patients found that questionnaires helped them to 
concentrate on their problems, with the UW QoL scoring highest (37%) and the 
Auckland quality of life questionnaire scoring lowest (22%). Approximately a 
quarter of respondents found no advantage to using the questionnaires, and this 
was consistent between questionnaires with no significant differences (table 2).  
 
Comparison of Patient Preferences of Questionnaires 
When asked to compare questionnaires, almost half of patients identified a specific 
questionnaire that they felt most helped them to describe their problems; FACT 
was the most commonly identified, followed by UWQoL 22 (30%) of 70 
respondents felt that any of the questionnaires would help them describe their 
problems (table 3). The most commonly cited reasons were that the questionnaire 
was relevant to their health problems (53%), that it was easy to understand (39%), 
and that it would help them state their problems to their doctor (30%). The order in 
which the component questionnaires appeared to the subjects in the survey 
questionnaire did not appear to affect their rating of usefulness (table 3). This was 
also not affected by whether they were new (untreated), or treated patients. 
 
When asked to rate the questionnaire least useful, most (approximately 60%) 
respondents indicated ‘not sure’.  Although the UW QoL was most cited, this only 
accounted for approximately 15% of respondents. The main reason for lack of 
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usefulness of a questionnaire was that it was not relevant to their health problems. 
Again responses did not vary significantly depending on whether patients were 
treated or new (untreated). 
 
 
Ideal questionnaire characteristics 
 60% of respondents (with a range of 43% to 71% when non-respondents were 
accounted for) would like to complete a questionnaire in the clinic, as they felt it 
would help them describe their health problems to their doctors (table 4). 40% of 
respondents (range 29%-57%) did not want to fill in a questionnaire, because they 
felt that it was not relevant to their health problems or that it took too long. 
 
Over half of respondents (range 47%-59% when non-respondents are accounted 
for) would prefer a short brief questionnaire, up to 20 questions long, and requiring 
less than 10 minutes to complete. Approximately a quarter were not concerned 
about the length of questionnaires or time taken to complete it. 
There were no significant differences in characteristics reported by new (untreated) 
and treated patients  
 
 
Discussion 
Key  findings 
A majority (60%) of head and neck cancer patients favoured using quality of life 
questionnaires as a method of communicating their problems to their doctors and 
of helping them concentrate on their problems, while a minority (about 25%) did not 
consider quality of life questionnaires to be of any major advantage. Most patients 
found the questionnaires easy to understand and relevant, and this applied to both 
new and treated patients. This has important implications for the use of quality of 
life questionnaires in routine clinical practice. 
 
It is reassuring that most patients felt that the quality of life questionnaires were 
generally easy to understand and relevant to their health problems and that length 
of questionnaire did not seem to affect patients’ perception of utility. Hence, the 
choice of questionnaire probably does not matter. Overall however, the FACT 
instrument appeared to be the most preferred.  
 
For the time being, the choice of questionnaire may be best left to the clinician 
involved, taking into consideration the aim for which quality of life is being 
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measured and what specific outcomes are of interest. While long questionnaires 
are likely to be used for research purposes, a shorter quality of life questionnaire 
option may be preferred for general clinical practice, and is consistent with the 
wishes of head and neck oncologists (6), as well as those of the patients. 
 
Limitations of study 
Due to the need to compare four questionnaires, the number of questions in the 
study questionnaire was large, and the possible resultant fatigue or boredom may 
have impacted on the participants’ responses. The design of the study attempted 
to address this issue by randomisation to four groups each with a different order of 
questionnaire presentation. However, because of the resultant four groups, 
numbers in each group are relatively low, and therefore may not have sufficient 
power to detect statistically significant differences between the sub-groups.  
 
Furthermore, although the questions on usefulness and comparison of 
questionnaires were straightforward and were piloted, they have not been validated 
in large scale studies, and may be a source of bias. In addition, some patients did 
not respond to some questions on preferences (table 4), either in the positive or 
negative, and this should be considered when interpreting the data, as potentially 
they may have had a negative view but did not want to express it. Alternatively, 
they may have had a positive view or they omitted the question in error. 
 
Small sample size also prevented subgroup analysis by site and treatment modality 
which may have a bearing on patient preference. For example, could the UWQOL 
be more suited for oral cancer (or surgical) patients and FACT better for laryngeal 
cancer (or radiotherapy) patients?    
 
Clinical applicability 
The majority of respondents would like to complete a questionnaire in the clinic, 
mainly because it assists them to describe their condition to their doctor. This is in 
contrast to the findings of clinician surveys, which show that doctors do not use 
quality of life questionnaires because of a combination of resource limitations and a 
perceived lack of proven clinical usefulness (5,6). It would therefore appear that 
there is a gap between the perceptions of the patients and their clinicians regarding 
the direct benefit of the use of quality of life questionnaires in routine clinical 
practice, and this needs to be addressed further.  
 
Furthermore, this study provides the basis for further research to evaluate the 
effects of using quality of life questionnaires in the consultation in head and neck 
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practice on improving communication and clinical outcomes. A mixed methods 
multi-centre trial to examine this is currently in the advanced stages of planning.  
 
Conclusions 
Patients report that HNC QLQs effectively describe their health concerns. Most are 
in favour of completing QLQs in clinic, as an aid for describing health problems to 
clinicians. There appears to be a difference between clinicians and patients 
regarding the perceived usefulness of QLQs in the clinic setting, which needs to be 
highlighted to clinicians. 
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Table 1:  Patient Characteristics           
   Total  Order of QLQ Presentation  
    1,2,3,4 2,3,4,1 3,4,1,2 4,3,1,2 
      n=74 n=18 n=18 n=19 n=19 
Male  50(68%) 16(89%) 10(56%) 8 (42%) 16(84%) 
Age, years , mean (sd) 65 (15) 69 (18) 63 (17) 62 (11) 66 (13) 
Patient Type New/Untreated 36(49%) 8 (44%) 9 (50%) 9 (47%) 10(53%) 
 Follow-up/Treated 38(51%) 10(56%) 9 (50%) 10 (53%) 9 (47%) 
Tumour Type Squamous 60(81%) 14(78%) 14(78%) 14 (74%) 18(95%) 
 Glandular 9 (12%) 2 (11%) 3 (17%) 3 (16%) 1 (5%) 
 Other 5 (6%) 2 (11%) 1 (6%) 2 (10%) 0 
Stage I 13(18%) 4 (22%) 2 (11%) 4 (21%) 3 (16%) 
 II 9 (12%) 0 4 (22%) 2 (11%) 3 (16%) 
 III 11(15%) 1 (6%) 2 (11%) 1 (5%) 7 (37%) 
 IV 22(30%) 4 (22%) 6 (33%) 7 (37%) 5 (26%) 
  No staging system 19(26%) 9 (50%) 4 (22%) 5 (26%) 1 (5%) 
Site Oral 24(32%) 5 (28%) 9 (50%) 6 (32%) 4 (21%) 
 Oropharynx 9(12%) 0 2 (11%) 3 (16%) 4 (21%) 
 Glottis 9 (12%) 2 (11%) 2 (11%) 1 (5%) 4 (21%) 
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Other ( incl hypo/nasopharynx)  29(39%) 9 (50%) 5 (28%) 9 (47%) 6 (31%) 
 
Follow Up Patients Only      
Surgery (Primary) Laryngectomy 3 (4%) 1 (6%) 0 1 (5%) 1 (5%) 
 Maxillectomy 2 (3%) 0 1 (6%) 1 (5%) 0 
 Mandibulectomy 1 (1%) 0 1 (6%) 0 0 
 Glossectomy 11(15%) 3 (17%) 5 (28%) 1 (5%) 2 (11%) 
Flap Local      
 Free flap single 28(38%) 6 (33%) 8 (44%) 8 (42%) 6 (32%) 
 Combination free flaps 3 (4%) 1 (6%) 0 2 (11%) 0 
Neck dissection Unilateral 29(39%) 8 (45%) 9 (50%) 5 (27%) 7 (37%) 
 Bilateral 5 (7%) 3 (17%) 1 (6%) 1 (5%) 0 
Radiotherapy None 24(32%) 3 (17%) 6 (7%) 8 (42%) 7 (37%) 
 Curative 14(19%) 2 (11%) 4 (22%) 7 (37%) 1 (5%) 
 Adjunct 16(22%) 5 (28%) 8 (44%) 3 (16%) 0 
Chemotherapy No 36(49%) 15(83%) 17(94%) 16 (84%) 18 (95%) 
 Yes 6 (8%) 2 (12%) 0 3 (16%) 1 (5%) 
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Table 2:  Questionnaire characteristics as perceived by patients  
                            n ( %) 
Questionnaire1 
UW QLQ 
Questionnaire2 
AQLQ 
Questionnaire3 
EORTC 
Questionnaire 4   
FACT HN 
  72 (100) 74 (100) 72 (100) 73 
        Relevant to my health problems 43 (60) 43(58) 49 (68) 54(74) 
 
        Easy to understand 57 (79) 57(77) 62 (86) 65(89) 
  Helps me to concentrate on the problems I have 28 (39) 16(22) 1926 27(37) 
 Neither helpful or unhelpful 17 (24) 19(26) 1724 18(25) 
 Too long 10 (14) 13 (18) 8 (11) 12 (16) 
 Difficult to understand 1 0 0 0 
 Too short 1 0 0 0 
 Annoying/intrusive because too long 1 2 (3) 1 1 
 Annoying/intrusive because difficult to understand 2 (3) 1 1 1 
 Annoying/intrusive because not relevant to my health problems 0 0 1 0 
 
No statistically significant differences between questionnaires were found using chi-squared test (p<0.05). 
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Table 3:  Head and neck cancer patient preferences of quality of life questionnaires 
 
  Total  Order of QLQ Presentation  
 
   1,2,3,4 2,3,4,1 3,4,1,2 4,1,2,3 
  
    n=70 n=16 n=17 n=19 n=18 
Which questionnaire helped most to describe health problems      
 Questionnaire 1 (UWQLQ)  10 4 2 3 1 
 Questionnaire 2 (AQLQ) 2 1 0 1 0 
 Questionnaire 3 (EORTC) 9 2 2 5 0 
 Questionnaire 4 (FACT HN) 13 3 3 2 5 
 Any of them 22 4 4 5 9 
 None of them 6 1 2 2 1 
 Not sure  4 1 3 0 0 
 A specific questionnaire 34 10 7 11 6 
Why was this the most useful? 
 Short  4 0 1 2 1 
 Easy to understand 27 5 5 8 9 
 Relevant to my health problems 37 9 11 6 11 
 Will help me state my health problems 21 4 7 4 6 
 Not sure  8 2 1 3 2 
  137
 
 
 
 
Other 
 
 
 
 
2 
 
 
 
1 
 
 
 
0 
 
 
 
1 
 
 
 
0 
Which questionnaire helped least to describe health problems 
 Questionnaire 1 (UWQLQ) 10 2 3 4 1 
 Questionnaire 2 (AQLQ) 2 1 1 0 0 
 Questionnaire 3 (EORTC) 8 2 0 3 3 
 Questionnaire 4 (FACT HN) 4 1 2 1 0 
 All of them 3 1 1 0 1 
 Not sure  30 6 8 8 8 
Why did you not like it? 
 Too long  6 1 2 2 1 
 Hard to understand 1 0 1 0 0 
 Not relevant to my health problems 17 6 6 3 2 
 Too intrusive 6 1 3 1 1 
 Not sure  19 5 6 6 2 
 Other  4 2 0 0 2 
 
No statistically significant differences between randomization groups were found using chi-squared test (p<0.05). 
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Table 4:  Ideal questionnaire characteristics as reported  
                by head and neck cancer patients  (n=70). 
If given a choice, would you like to fill in a questionnaire at the clinic? 
 Yes - helps me to stats/describe health problems to the doc 25 
 Yes - helps me to concentrate on problems I have 5 
 No - questionnaire takes too long 9 
 No - questionnaire difficult to understand 0 
 No - questionnaire not relevant 11 
 No response 20 
 
Would you prefer a short brief questionnaire or a long detailed one? 
 Short brief 36 
 Long detailed 5 
 Either  22 
 Neither  4 
 No response  3 
 
Time required to complete questionnaire? 
 <60 seconds 2 
 <5 mins  18 
 6-10 mins 17 
 11-20 mins 18 
 >20 mins 0 
 Doesn't matter 12 
 Other  0 
 No response  3 
Number of questions in a questionnaire?  
 <5  2 
 5 to 10  14 
 11 to 15  8 
 16 to 20  9 
 > 20  8 
  Doesn't matter 21 
 No response 8 
 
No significant differences were found between the randomization arms for any of 
the above factors using chi square test. 
 
Patients’ views on QOL questionnaires 
Figure 1: Questionnaire characteristics as perceived by head and neck 
cancer patients. 
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Appendix 1 
Comparison between quality of life measures 
 
Quality of Life Questionnaire Study 
Questionnaire 1 
 
 
1. Regarding questionnaire 1, how would you describe this questionnaire?  
 
                                     Circle one 
 
a. Relevant to my heath problems   Yes   No
   Not sure  
 
b. Easy to understand    Yes   No
   Not sure 
 
c. Too long     Yes   No
   Not sure 
 
d. Difficult to understand    Yes   No
   Not sure 
 
e.   Too short     Yes   No
   Not sure 
 
 
2. How did you find questionnaire 1?  You CAN circle MORE than one choice, 
if you wish 
 
A) Helps me to state/ describe my health problems to the doctor. 
  
B) Helps me to concentrate my mind on the health problems I have. 
 
C) Neither helpful or unhelpful. 
 
D) Annoying / intrusive because it is too long. 
 
E) Annoying / intrusive because it is difficult to understand. 
 
F) Annoying / intrusive because it is not relevant to my health 
problems or complaints. 
 
 
3. Any additional comments about the questionnaire you wish to make? 
 
 
 
 
Patients’ views on QOL questionnaires 
 
 
Appendix S2:  
Value of completion of a quality of life questionnaire 
Quality of Life Questionnaire Study 
 
 
Now please think back to all 4 questionnaires 
1. Of the 4 questionnaires, which ONE do you think would help you MOST to 
state / describe your health problems to the doctor?  
 
A) Questionnaire  1   E)  ANY of them 
B) Questionnaire 2   F)  NONE of them 
C)   Questionnaire 3   G) Not sure 
D)   Questionnaire 4 
 
2.  Why did you find  the questionnaire you identified above in question  
     1 helpful?  You can circle MORE than one choice if you wish. 
 
A) Short 
B) Easy to understand 
C) Relevant to my health problems/complaints 
D) Will help me state / describe my health problems to the doctor 
E) Not sure  
F) Other - please state 
_______________________________________________ 
 
3.  Of the 4 questionnaires which ONE do you think would help you 
     LEAST to state / describe your health problems to the doctor ? 
 
A) Questionnaire  1   E) All of them  
B) Questionnaire 2   F) Not sure 
C)   Questionnaire 3     
D)   Questionnaire 4 
 
4. Why do you not like the questionnaire you identified above in  
     question 3?  You can circle MORE than one choice if you wish. 
 
A)  Too long 
C) Hard to understand 
D) Not relevant to my health problems 
E) Too intrusive 
F) Not sure 
G) Other - please state ______________________________ 
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5. If given a choice, would you like to fill in a questionnaire at the clinic, and 
why? 
A) YES - Helps me to state/ describe my health problems to the 
doctor.  
B) YES - Helps me to concentrate my mind on the health problems I 
have. 
C) NO - because questionnaire takes too long. 
D) NO - because questionnaires are  difficult to understand. 
E)    NO - because questionnaires are often not relevant to my health  
        problems or complaints 
 
 
6. Would you prefer a short brief questionnaire or a long detailed one? 
A) Short brief questionnaire asking a few questions. 
B) Long detailed questionnaire asking a few questions. 
C) Either is fine. 
D) Neither - I do not want to fill any questionnaires. 
 
 
7. Which of the following would be acceptable to you as a questionnaire about 
your health filled in clinic? 
c. Time required to complete questionnaire (please select only one 
choice) 
 
i. less than 1 minute  ii. Less than 5 minutes iii. 6-10 minutes                
iv. 11-15 minutes    v. 16-20 minutes  vi. more than 20 minutes 
vii. duration does not matter       viii. Other: please state………… 
 
d. number of questions included in questionnaire (please select only one 
choice): 
 
i. less than 5 questions   ii. 5-10 questions     iii. 11-15 questions  
 
iv. 16-20 questions  v. 21-25 questions  vi.  more than 25 questions 
vii. number of questions does not matter  viii. Other : please state…
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Summary, discussion and conclusions / samenvatting 
Parts published as: Mehanna HM. Will measuring quality of life in 
head and neck cancer alter individuals' treatment? Curr Opin 
Otolaryngol Head Neck Surg. 2007 Apr;15(2):57-62.  
Chapter 8 
Summary of main findings 
I have provided detailed discussion and conclusions for each study in its own 
chapter. In this chapter, I discuss and summarise the main conclusions of the 
research thesis as a whole. I then provide suggestions as to how the findings of 
this research may be utilised and applied to clinical practice. Finally, I discuss the 
areas of important further research that are suggested by the findings of this 
research.  
For this thesis, we set out to achieve two main objectives. The first was to attempt 
to characterise the QoL of HNC patients over time, especially in the longer term, 
and to understand its determinants and its association with survival. The second 
was to begin to explore means of improving QoL assessment, especially routinely 
in a clinical setting. This was to be examined by exploring the reasons for poor 
adoption of QoL tools in the clinical setting and by attempting to determine the QoL 
tools most appropriate for use by HNC patients and by HNC clinicians. 
 
To achieve these objectives, we started by reviewing the current knowledge base 
on QoL in HNC in Chapter 2. We found that QoL usually decreases immediately 
after treatment for HNC, then gradually increases to pre-treatment levels, usually 
by 12 months. QoL appears to be similar following chemoradiotherapy or surgery 
for HNC, despite differences in functional deficits.  
 
Many clinicians, researchers and professional bodies have called for QoL to be an 
integral part of assessment of outcomes in head and neck cancer (HNC). Its 
measurement should be routine, prospective, and long-term; using brief, patient-
reported, validated tools, with both general and disease specific modules. As 
patients’ perceptions differ significantly from doctors’, QoL should be incorporated 
in to the management pathway of the patient to help improve patient care. We also 
identified a considerable need for more research into QoL in head and neck cancer 
to enable the above to happen. 
 
In Chapter 3, we then examined the change over time of the quality of life of long-
term (10 year) survivors of a cohort of patients that had had assessments of short-
term QoL. We also studied the association between prognostic indicators of quality 
of life, including socio-demographic factors (age, gender, smoking, alcohol), 
disease–related or medical factors (disease extent, disease site - mouth, larynx, 
pharynx- treatment type, etc) and long-term quality of life, assessed by measures 
of global QoL, depression and physical symptoms in the aforementioned patient 
cohort.  
 146
Summary, discussion and conclusions 
 
Our findings demonstrated that long-term (10 year) survivors of head and neck 
cancer report decreases of 11-15% in the level of their overall QoL, despite having 
improved above their baseline QoL in the short -term. This was, as far as we know, 
the first report of such long-term follow-up and of such a drop. We could not from 
the design of the study, determine when that drop actually occurred, and whether it 
was related to any new co-morbidities that have developed in the interim. This will 
require further work. It was clear, however, that baseline QoL was significantly 
associated with long-term QoL, whereas QoL at one year post-treatment, and 
tumour stage and treatment were not.  
 
We were also interested in the relationship between QoL and psychosocial factors 
with long-term survival from head and neck cancer. Studies had shown an 
association between quality of life and survival of sufferers of several types of 
cancer, including breast, lung cancer and melanoma (1-3). This was mainly 
demonstrated in patients undergoing palliative treatment. We aimed to explore 
whether a similar association between QoL and psychosocial factors exists with 
long-term survival in head and neck cancer.  
 
In Chapter 4, we therefore undertook a study (4) to examine the association of QoL 
and psychosocial factors with long-term survival. We too found that baseline QoL in 
our cohort of 200 patients was not associated with long-term survival). In contrast, 
post-treatment, those with low quality of life at one year had significantly increased 
odds of mortality [2.5 (95% CI 1.4, 4.3, p=0.001)] and with head neck pain, even 
after adjustment for co-variates. Survival was not associated with the psychological 
status of the patient. 
 
We then undertook a systematic review of the literature in Chapter 5. We found 
that the above findings have since been confirmed in other cohorts (5-14). In all 
studies, at baseline, overall QoL was not associated with survival. However, 
expression of intense psychosocial complaints, higher self-perceived physical 
ability and self-reported high physical functioning were significantly associated with 
increased survival. Uncertainty about the diagnosis and treatment was found to be 
a negative prognostic indicator, as was being single, poor cognitive function, 
baseline fatigue, pessimism and alcoholism. The relationship is currently neither 
strong nor proven. It may be that this is because there is no real association. 
However the multiplicity of studies confirming similar types of relationships suggest 
that there is likely to be an association. Therefore the difficulties in establishing this 
association may be due to methodological inconsistencies - because of small 
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sample sizes under study, and the considerable variability in definitions and 
methodologies. More work is needed to standardise the definitions and designs 
used, before multicentre studies can examine this topic more fully. 
 
It is not known whether an association between quality of life and survival is simply 
a reflection of the patient’s physical and psychological state when they have a 
recurrence that is impairing their function, and also causing stress and depression. 
Alternatively it may be that there are more involved physiological processes, such 
as   
tumour related factors eg Insulin growth factor-1, which may be secreted by the 
tumour which may result in fatigue, pain and subsequent impairments of quality of 
life. Finally, there may be a different explanation and causative mechanism – the 
effect of psychology and quality of life on behaviour and physiological processes 
may result in better immunity and other tumour control mechanisms, resulting in 
better survival. This is suggested by some studies that have found that baseline 
personal traits eg pessimism (12) may be related to survival from head and neck 
cancer. 
 
In the second section of the thesis, we have aimed to examine clinicians’ views on 
the routine use of QoL in the clinical setting, and to identify any impediments to the 
implementation of routine qoL assessment in the clinic.  To do this, in Chapter 6, 
we undertook a cross-sectional survey of HNC clinicians in Australia and New 
Zealand. We found that most (88%) head and neck clinicians were in favour of the 
routine use of a short QoL assessment tool in the clinic. Yet, only a minority (13%) 
were currently using any - mainly for research purposes. The main impediments to 
routine use in a clinical setting were lack of time and manpower resource, and lack 
of relevance for clinical practice. These findings were confirmed by a survey of UK 
head neck clinicians that we later undertook with colleagues (15). 
 
As there are two partners in the consultation and clinical process, we also felt that it 
was important to explore the patients’ perspective on the use of QoL assessment in 
the clinic. If patients were not willing to use the QoL instruments or did not find 
them useful, then there would be little imperative to introduce them into routine 
clinical practice. In Chapter 7, our study showed that most (74%) of patients felt the 
questionnaires were relevant to their medical problems and would help them 
describe their problems to their clinicians. Most (89%) found the questionnaires 
easy to understand. Half of the patients preferred a specific questionnaire, with 
FACT questionnaire being the most commonly identified. 60% of respondents 
would like to complete questionnaires in the clinic as they felt it would help them 
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describe their health problems to their clinicians. However 40% did not want to use 
questionnaires as they felt it was not relevant to their condition or took too long. 
 
Conclusions 
 QoL is a self-reported, subjective, multidimensional phenomenon that changes 
over time  
 QoL is an integral part of assessment of outcomes in head and neck cancer 
(HNC).  
 QoL usually decreases immediately after treatment, then gradually increases to 
pre-treatment levels, usually by 12-18 months. 
 A significant drop in late QoL is observed at 10 years following diagnosis, which 
was predicted by pre-treatment QOL. None of the socio-demographic, disease 
or treatment related factors predicted long-term QOL on univariate analysis, but 
this may be due to the small sample size. 
 Post treatment QoL appears to be a strong and significant predictor of long- 
term survival from head and neck cancer. Some pretreatment personality traits 
and some other post-treatment psychosocial factors (eg head and neck pain, 
eating score, speech and SF-36 physical functioning) appear to be also 
significantly associated with long term survival. 
 Most HNC clinicians do not use a QoL measure routinely, as they feel that it is 
too time consuming and has no proven benefit for clinical management. 
 Patients report that HNC quality of life questionnaires effectively describe their 
health concerns. Most are in favour of completing these questionnaires in clinic, 
as an aid for describing health problems to clinicians. 
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Discussion and applications of this research 
Providing patients with better information on course of disease and prognosis. 
Patients need and want information regarding their illness and treatment options. 
Evidence suggests that by providing them with effective information regarding their 
condition and treatment, patients’ satisfaction and quality of life is improved and 
their anxiety is reduced (16). Yet most head and neck cancer patients still feel that 
the information they receive from multi-disciplinary teams is inadequate, especially 
during the 3-6month of the post-operative period (17). 
 
Early literature reports on QoL in HNC were retrospective cross- sectional studies 
of groups of patients who had received treatment. These studies gave us some 
insight into the problems that these patient groups, eg laryngectomees, were 
experiencing post-operatively. However, the information was lacking in that it did 
not inform us of how their symptoms and QoL had developed or changed during 
and after treatment. In the early 1990s, prospective longitudinal studies started 
appearing in the literature (17,18). These and subsequent studies (19-21) describe 
the journey of HNC patients through treatment and for several years beyond. Such 
studies have been invaluable in enabling clinicians to gain an objective insight into 
the effects that their treatments were having on their patients. Importantly, this 
information is essential to enable the provision of better information and informed 
consent to patients. In addition, by identifying the ‘critical’ periods during the patient 
journey when they are most likely to have problems and their nature, clinicians are 
more able to anticipate these problems and intervene when they occur. More 
recently, long-term (10 year) QoL follow-up has been reported, thus beginning to 
complete the picture, with other cohorts soon to report their long term results. 
 
Consider a patient who is about to embark on a course of chemoradiotherapy. One 
knows from the studies above that their QoL will drop precipitously over the next 
three months. This QoL deterioration will ‘bottom out’ at about 3-6 months from 
diagnosis, during which patients require the greatest support. Their QoL will then 
start improving at about 6 months, and continue to improve for the next six months. 
QoL will then usually start to plateau, and may improve at a much slower rate over 
the next couple of years. When discussing treatment and prognosis with patients at 
our clinic, we often present them with a graph of the likely course of symptoms and 
quality of life (see Figure 1). Anecdotally, it is our experience that patients find this 
information very valuable, as they know what to expect. Importantly when they are 
experiencing their worst symptoms, they are aware that this is likely to be transient, 
and that their QoL is likely to improve in the future.  
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Assessing new and existing treatments and techniques 
In the curative setting, QoL considerations are especially important when choosing 
between treatments with similar survival rates, or when comparing new treatments 
to established ones in a research setting (25). Indeed, most research funding 
bodies now require that QoL data be collected routinely in trials examining new 
treatments. 
 
By assessing patients’ QoL, we are able to assess whether existing and new 
management interventions result in improved patient-reported outcomes and QoL. 
Such findings can be utilised to direct technical considerations when options 
present. For example, several studies have shown that for oropharyngeal 
resections, primary closure, when feasible, results in better swallowing outcomes 
than reconstruction with a free flap (22). Intensity modulated radiotherapy is 
another such instance where evaluation of QoL is essential. The multi-centre 
randomised study of parotid sparing intensity-modulated radiotherapy in patients 
with head and neck cancer (PARSPORT) study examined the effects of IMRT to 
spare the contra-lateral parotid compared to normal radiotherapy for oropharyngeal 
tumours (23). Its outcome measures are functional and QoL-based due to the 
potential significant effects on patients’ well being. 
 
Improving the consultation and follow-up 
HNC patients spend the largest proportion of their time with us attending the follow-
up clinic after their treatment.  It is clear from both anecdotal reports and the limited 
research available (16, 30) that HNC clinics are often aimed at ‘cancer 
surveillance’. They are mainly concerned with treating cancer and detecting 
recurrence, with less or little emphasis on addressing and improving patients’ 
health related QoL.  Furthermore the quality and outcomes of consultations can 
vary considerably. This is of concern when, as mentioned previously, HNC and its 
treatment can cause frequent and sometimes devastating effects on patients QoL, 
which may improve if detected and addressed. 
 
Use of routine health-related QoL assessment in a clinical oncological setting has 
been shown to improve patient- clinician communication and is associated with a 
concomitant improvement in health-related QoL and emotional functioning of 
patients (31). Detmar et al (32) also concluded from a randomised trial that use of 
questionnaires in a routine clinical oncological setting facilitated patient – clinician 
communication, and improved clinician awareness of their patients’ HRQoL issues 
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(31). The same was found by Taenzer (33). To date, no such work has been done 
in HNC.  
 
Furthermore, several studies have examined the use of health-related QoL data 
collection by ‘touch –screen’ technology and have found it to be widely accepted 
and easy to use by patients (32,34), including those with HNC in a pilot study by 
Millsopp (34). These tools can be utilised to facilitate routine HRQoL assessment in 
the clinic, to provide clinicians with timely longitudinal QoL information about the 
patient and to overcome some of the resource restrictions preventing clinicians’ 
participation. 
 
From this research, we now know that most head and neck cancer patients do find 
the routine use of QoL tools in the clinical setting useful. We have also explored 
which tools they most prefer. Furthermore we have explored the views of clinicians 
and identified the main impediments to using QoL tools in clinical practise. This 
paves the way for further research into better integration of these tools in the 
clinical setting in head and neck cancer/  
 
Screening and Interventions to improve quality of life and psychosocial well-being 
The ultimate aim of measuring QoL must be to improve or at least to prevent the 
deterioration of quality of life in HNC patients. One obvious target would be the 
psychosocial domain as it is heavily affected by head and neck cancer and its 
treatment. Many patients exhibit high levels of persistent psychological and 
emotional distress. There has been some research into the causes and predictors 
of psychosocial well-being and their impact on overall quality of life of patients with 
head and neck cancer. However, contradictory findings are often reported and few 
conclusions can be drawn from the literature. This is mainly attributable to the 
variety of definitions and methodologies used, the small sample sizes examined 
and the often retrospective nature of the studies. By identifying the predictors of 
long-term QoL in this research, we may be able to help focus research to particular 
areas in this field.  
 
There are a few interventional studies that have aimed to improve psychosocial 
well-being and overall quality of life in patients with head and neck cancer. These 
have included social rehabilitation programs (34), group psychological therapy 
(using a combination of cognitive and behavioural techniques) (35) and a one week 
psycho-educational program. Some of these programmes have shown benefit. 
Recent evidence suggests that patients prefer individualised forms of psychosocial 
intervention (mainly cognitive behavioural therapy) (36). Findings are not consistent 
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however, as the largest study, evaluating a psychosocial support program in 
Sweden, showed no benefit (37). 
 
The field of screening and intervention for dysfunction and disabilities holds a lot of 
promise, as does the design and evaluation of interventions to improve QoL in 
head and cancer. Knowledge of the determinants of long-term quality of life and 
the risk factors for poor QoL, as explored by this research, may aid clinicians in 
identifying patients who are at risk of poor quality of life earlier, and targeting them 
with more support and rehabilitation. However, much more work is needed in this 
field to standardize study designs and outcome measures and to evaluate the 
different interventions. 
 
Future research avenues 
Quality of life research has included research into patient preferences and 
priorities, which only a few decades ago, were never considered by physicians. List 
et al showed in 2000 (24) that patients’ priorities lie in achieving cure, followed by 
survival for as long as possible, then followed by QoL issues. This understanding 
has helped clinicians recommend management to patients, and has been used to 
support the development of more aggressive treatment modalities in the hope that 
they would improve survival. However, List’s study also showed that there was 
significant variability between patients and that it was important to seek patients’ 
views and not to make assumptions. Furthermore, it has been long been 
established that patients’ and clinicians’ aims and priorities from treatment diverge 
considerably (25). Thus quality of life research has also helped teach us to become 
more patient-focused, and to defer to our patients’ wishes, as esoteric as some of 
those wishes may seem to us clinicians. 
 
In the palliative scenario, QoL is usually the most important treatment goal. Both 
patients and clinicians report wanting to discuss QoL issues, but also report that 
confusion regarding who should initiate the discussion appears to hamper this 
process (26). By measuring these patients’ QoL routinely using patient-centred 
tools, this confusion can be overcome, and the issues important to the patient and 
their family can be addressed. 
 
In the curative setting, QoL considerations are especially important when choosing 
between treatments with similar survival rates. Within our multi-disciplinary 
meetings and clinics, we regularly encounter decisions on which treatments to 
recommend. These often (should) include quality of life issues, and the decision is 
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often to recommend either treatment and enable the patient to decide according to 
their preferences.  
 
One problem frequently faced is that there is a distinct lack of high quality 
prospective comparisons of QoL outcomes for different treatments providing 
equivalent cure rates. Such difficult situations including comparing radiotherapy to 
conservation laryngeal surgery for a T1/T2 laryngeal tumour; or considering 
surgery compared to chemoradiotherapy for a T3 tonsillar tumour. The literature 
consists mainly of retrospective and some prospective reports on small groups of 
patients treated by one or other treatment option, with all the inherent selection and 
other biases. Indeed, despite all the studies on chemoradiotherapy, there is little 
prospective comparative evidence between the QoL of patients with 
laryngectomies compared to those receiving organ sparing treatment, especially 
with regards swallowing (27,28). This is partly due to the understandable difficulty 
in running randomized trials of these treatments. By prospectively collecting QoL 
outcome measures routinely and pooling them between centres, we may be in a 
better position to provide our patients with the necessary information to make these 
choices. Needless to say that much more comparative work is required in this area, 
although there are certainly some good efforts currently directed in this field. 
 
Our research showed that patients appear to show a drop in QoL in the long-term. 
When and why this occurs is not yet known. Validation of these findings by other 
long-term cohorts is necessary. Further elucidation of the determinants of long-
term QoL, including examination of the role of co-morbidity in this process, would 
also be important. 
 
Long-term survival from head and neck cancer appears to be related to some 
psychosocial factors such as cognitive function, fatigue, self efficacy and 
expressed uncertainty.  However this relationship is not currently clear in the 
literature. There is significant variability and sometimes contradiction in the 
reported results, and this may suggest the lack of any real association. It may also 
reflect the considerable heterogeneity in definitions, methodologies, and designs, 
and sizes of the studies.  Standardisation of these in the context of multi centred 
trials and the examination of post treatment psychosocial factors should be 
undertaken in an effort to elucidate this relationship further.   
 
There appears to be a significant gap between the current status of QoL 
measurement in clinical practice and the ideal, or even what the clinicians 
themselves aspire to. This gap seems to exist because current quality of life 
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questionnaires do not appear to address the needs of the head and neck clinician, 
who would like a short consensus QLQ, and which ideally could also be used to 
assist patient management. Further assessment of current quality of life 
questionnaires is needed to identify which of these would best fulfil these criteria, 
and whether modification of existing questionnaires is required to achieve these 
aims. It is also important that the assessment ensures that the selected quality of 
life questionnaire also fulfils the needs of the patients.  
 
More work needs to be undertaken to address the impediments to use of QoL tools 
in routine clinical practice in head and neck. Data capture techniques are already in 
development in the head and neck to improve the incorporation of QoL tools in the 
clinic. However, more research is required to make process of acquisition of the 
data quicker and less laborious for the patients. Furthermore, research is needed 
to evaluate the effects of using quality of life questionnaires on improving 
communication and clinical outcomes in the consultation. A mixed methods multi-
centre trial to examine this is currently in progress. 
 
The majority of patients appeared to favour the use of quality of life assessment in 
the clinic. Those who did not favour its use feel that it takes too long or may not be 
relevant to their condition. This would suggest therefore that there are several 
opportunities for research and improvement in this field. Firstly, identification of the 
quality of life tool most preferred particular specific head neck patient groups is 
necessary, especially for the most frequent sites – oral and laryngeal cancer. This 
is currently in progress. Secondly, refinement and better understanding of meaning 
of the results of quality of life scores is needed. This understanding will better guide 
clinicians and researchers as to how to better utilise these scores for the 
improvement of patients’ quality of life. Specifically, more work is needed on the 
clinical relevance of the scores of common quality of life tools and the meaning of 
changes on these scores. To date, the majority of studies have been reported as 
changes in units of the quality of life measurement used to assess the patients, 
along with the statistical significance of the difference.  For example, a new 
intervention A demonstrates a benefit of a mean difference of 5 units over the 
current treatment, when assessed by quality of life tool X. This may be statistically 
significant difference compared to the current treatment eg p=0.03. However, this 
does not provide information on the clinical significance of the changes detected, 
making QoL studies difficult to understand and translate into every day clinical 
practice. This, in my view, is a significant flaw in QoL studies in HNC that only 
recently has started being addressed (29). 
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To understand the implications of the minimum clinically important difference, 
consider further the above example, which was given in a lecture by Jay Piccirillo 
(personal communication) at the British Academic Conference of 
Otorhinololaryngology. If the minimum clinically important difference  for QoL tool X 
used above is 10 units, then actually the QoL advantage from this new intervention 
A is probably not clinically relevant, and thus unlikely to benefit most patients. 
Studies reporting QoL outcomes should therefore be reported using the MCID of 
the QoL tool used and the percentage of patients achieving a difference equal to or 
larger than the minimum clinically important difference .  
 
Let’s consider the above example further. If the study reports that the above 
intervention A resulted in a mean benefit of 20 units, which is twice the minimum 
clinically important difference, over the existing treatment then we can be more 
confident that this new intervention A is more beneficial than the current treatment. 
Even more reassuring would be a report that for example, 80% of patients 
receiving the new intervention A achieved a benefit of more than 10 units (the 
minimum clinically important difference), compared to 50% of patients receiving the 
existing treatment. This format is easily understood by clinicians and more relevant 
to clinical practice. Indeed, it is also easier to communicate to patients – one can 
confidently say to their patients that intervention A in the above study provides 80% 
of patients with benefit, and that it is more effective than the current treatment. 
However, to enable this to occur, more work is needed to identify the minimum 
clinically important differences for each of the commonly used QoL tools. 
 
Work is also needed on how scores of different questionnaires compare to each 
other, and whether they are examining similar aspects. This is especially important 
in understanding and comparing the results of different studies that use different 
QoL measures. We have instituted a multicentre randomised study to examine this. 
As part of the refinement of the use of quality of life tools, better understanding is 
needed of the significance of life utility tools eg time trade off and health utilities 
index, and their role in head and neck cancer.  
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Samenvatting 
Samenvatting 
Het in dit proefschrift beschreven onderzoek heeft twee doelstellingen. In de eerste 
plaats is getracht de kwaliteit van leven van patiënten met hoofd-halskanker in de 
tijd (in het bijzonder op de lange termijn) te schetsen en de determinanten hiervan, 
ook in relatie tot de overleving, te doorgronden. Het tweede doel was initieel 
onderzoek te doen naar mogelijkheden om de meting van kwaliteit van leven te 
verbeteren, in het bijzonder de periodieke meting in de kliniek. Daartoe werd 
onderzocht waarom de meetinstrumenten van kwaliteit van leven in de kliniek 
weinig worden gebruikt en tegelijkertijd werd nagegaan welke instrumenten het 
meest geschikt zijn voor gebruik door patiënten en hulpverleners. 
 
In het kader van deze doelstellingen werd allereerst een inventarisatie verricht van 
wat er tot tot nu toe bekend is over kwaliteit van leven bij hoofd-halskanker. Dit 
wordt beschreven in hoofdstuk 2. Hieruit kwam naar voren dat de kwaliteit van 
leven doorgaans direct na de behandeling afneemt en daarna, geleidelijk in 12 
maanden, weer toeneemt tot het niveau van voor de behandeling. Ondanks 
verschillen in functieverlies blijkt de kwaliteit van leven na chemoradiotherapie en 
na chirurgie gelijk te zijn. 
 
Veel clinici, onderzoekers en professionele instellingen hebben ervoor gepleit voor 
meting van kwaliteit van leven als integraal onderdeel bij het beoordelen van het 
resultaat van de behandeling van hoofd-halskanker. De evaluatie van de kwaliteit 
van leven zou routinematig, prospectief en ook op lange termijn moeten worden 
gedaan. Hiervoor moeten gevalideerde meetinstrumenten, met zowel algemene als 
ziekte-specifieke modules worden gebruikt, die kort zijn en de mening van de 
patiënt zelf weergeven. Aangezien de perceptie van de patiënt aanzienlijk verschilt 
van die van de arts, moet kwaliteit van leven worden betrokken bij het 
behandelpad van de patiënt om zo de zorg te verbeteren. Om bovenstaande te 
kunnen verwezenlijken is  meer onderzoek naar kwaliteit van leven bij hoofd-
halskankerpatiënten noodzakelijk. 
 
In hoofdstuk 3 wordt verslag gedaan van een onderzoek naar de verandering van 
de kwaliteit van leven in de tijd bij lange termijn overlevers (10 jaar) van een cohort 
patiënten, bij wie ook een meting was verricht kort na de behandeling,. Bovendien 
werd het verband tussen prognostische factoren voor kwaliteit van leven, inclusief 
sociodemografische factoren (leeftijd, geslacht, roken, alcohol gebruik), ziekte 
gerelateerde factoren of medische factoren (tumor uitbreiding, de plaats van de 
tumor – mond, larynx, farynx – aard van de behandeling, etc.) en kwaliteit van 
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leven op lange termijn, gemeten door middel van de globale kwaliteit van leven, 
depressie en lichamelijke klachten bij het boven genoemde cohort. 
 
Onze bevindingen laten zien dat lange termijn (10 jaar) overlevers van hoofd-
halskanker een vermindering van 11- 15% in niveau van kwaliteit van leven 
rapporteren, ondanks het feit dat zij op korte termijn een verbetering aangaven ten 
opzichte van de nulmeting. Dit is, voor zover wij weten, de eerste rapportage van 
een lange termijn follow-up met een dergelijke daling in niveau van kwaliteit van 
leven. De aard van het onderzoek laat een bepaling van het tijdstip van optreden 
van de niveaudaling niet toe. Ook was het niet mogelijk een relatie vast te stellen 
met eventueel nieuw ontwikkelde co-morbiditeit, die zich in de tussentijd voordeed. 
Dit vereist verder onderzoek. Het was echter duidelijk dat de uitgangswaarde van 
kwaliteit van leven significant was geassocieerd met de kwaliteit van leven op 
lange termijn, terwijl de kwaliteit van leven een jaar na de behandeling en het 
tumor stadium geen associatie vertoonden. 
 
Wij waren ook geïnteresseerd in de relatie tussen kwaliteit van leven en 
psychosociale factoren met de lange termijn overleving bij hoofd-halskanker. 
Literatuuronderzoek laat zien dat er een relatie bestaat tussen kwaliteit van leven 
en overleving bij verschillende kankersoorten, waar onder borstkanker, longkanker 
en melanoom (1-3). Dit verband werd vooral aangetoond bij patiënten die palliatief 
werden behandeld. Wij wilden onderzoeken of een dergelijk verband tussen 
kwaliteit van leven en psychosociale factoren met lange termijn overleving bij 
hoofd-halskanker bestaat. 
 
In hoofdstuk 4 wordt dit onderzoek beschreven (4) waarin het verband tussen 
kwaliteit van leven en psychosociale factoren met lange termijn overleving is 
bestudeerd. Ook wij vonden dat de uitgangswaarde van kwaliteit van leven in een 
cohort van 200 patiënten geen associatie vertoont met lange termijn overleving. Dit 
is niet in lijn met de meting na de behandeling: degenen met een lage van kwaliteit 
van leven 1 jaar na de behandeling hadden een significant verhoogde odds ratio 
voor overlijden [2,5 (95% BI 1,4; 4,3; p=0,001)] en voor pijn in het hoofd-
halsgebied, ook na correctie voor co-variabelen. Overleving was niet geassocieerd 
met de psychosociale status van de patiënt. 
 
De in hoofdstuk 5 beschreven systematische literatuurstudie toonde aan dat de in 
hoofdstuk 4 gerapporteerde resultaten sindsdien zijn bevestigd in andere cohort 
studies (5-14). In vrijwel alle artikelen was de kwaliteit van leven bij de nulmeting 
niet geassocieerd met de overleving. Echter, het uiten van psychosociale klachten, 
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een beter lichamelijk zelfbeeld en het subjectief beter lichamelijk functioneren 
vertoonden een significant verband met een langere overleving. Onzekerheid met 
betrekking tot diagnose en behandeling bleek een negatief prognostische waarde 
te hebben, zoals ook het niet hebben van een partner, een slechte cognitieve 
functie, vermoeidheid voor de behandeling, pessimisme en alcoholisme. Deze 
relatie is tot op heden noch sterk, noch bewezen. De reden hiervan kan zijn dat er 
geen echte associatie is. Het aantal studies dat dergelijke verbanden bevestigen 
suggereert echter dat er waarschijnlijk wel een relatie is. Het probleem om dit 
verband vast te aan te tonen is mogelijk toe te schrijven aan methodologische 
tekortkomingen – kleine steekproef omvang in de studie en de aanzienlijke 
variabiliteit in definities en methoden. Er moet meer aandacht worden besteed aan 
het standaardiseren van de definities en de studieopzet die worden gebruikt 
voordat in ‘multicentre’ verband dit onderwerp meer in extenso kan worden 
onderzocht. 
 
Het is niet bekend of een verband tussen kwaliteit van leven en overleving 
eenvoudig weg een weerspiegeling is van de lichamelijke en psychologische 
toestand van een patiënt die een recidief heeft waardoor het functioneren wordt 
belemmerd en ook stress en depressieve gevoelens optreden. Anders gezegd is 
het mogelijk dat er meer psychologische processen bij zijn betrokken, zoals tumor 
gerelateerde factoren, zoals Insuline groeifactor-1, die mogelijk door de tumor 
wordt afgescheiden en resulteert in vermoeidheid en pijn met een negatieve 
invloed op de kwaliteit van leven. Ten slotte is er een mogelijk andere verklaring en 
oorzakelijk mechanisme: het effect van de psyche en kwaliteit van leven op gedrag 
en psychologische processen zou een betere immuniteit en andere tumor controle 
mechanismen tot gevolg hebben en kunnen resulteren in een betere overleving. 
Dit wordt ingegeven door een aantal onderzoeken waarin werd gevonden dat 
bepaalde persoonlijkheidskenmerken gemeten voor de behandeling, zoals 
pessimisme, gerelateerd zijn aan de overleving van hoofd-halskanker. 
 
In het tweede deel van dit proefschrift wordt beschreven hoe de mening van artsen 
over routine kwaliteit van leven meting in de kliniek werd gepeild en wat de 
hindernissen zijn die systematische evaluatie hiervan in de weg staan. In hoofdstuk 
6 wordt een transversaal onderzoek onder hoofd-halskankerspecialisten 
beschreven, dat werd uitgevoerd in Australië en Nieuw Zeeland. Hierbij werd  
gevonden dat de meeste hoofd-hals specialisten positief staan tegenover het 
routine gebruik van een kwaliteit van leven meetinstrument dat weinig tijd in beslag 
neemt. De praktijk is echter dat slechts een minderheid (13%) een dergelijk 
meetinstrument gebruikt en dan nog voornamelijk voor onderzoeksdoeleinden. De 
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belangrijkste reden om er van af te zien was een gebrek aan tijd en mankracht. 
Daarbij werd ook de relevantie voor de dagelijkse praktijk niet gezien. Deze 
bevindingen werden bevestigd in een onderzoek onder collega hoofd-hals 
specialisten in Engeland, dat wij in een latere fase deden. (15). 
 
Aangezien er in de consultatie en het klinisch beloop twee partners zijn, was het in 
onze ogen ook belangrijk het gebruik van kwaliteit van leven meetinstrumentarium 
vanuit patiënten perspectief te bekijken. In het geval dat patiënten het nut van 
kwaliteit van leven evaluatie niet zien en er geen gebruik van zouden willen maken, 
zou er weinig noodzaak zijn dit in de dagelijkse praktijk te gaan opnemen. In 
hoofdstuk 7 staat beschreven dat de meeste patiënten (74%) vonden dat de 
vragenlijsten relevant waren voor hun medische problemen en zouden bijdragen 
deze aan de hulpverleners duidelijk te maken. De meesten (89%) vonden de 
vragenlijsten gemakkelijk te begrijpen. De helft gaf de voorkeur aan één specifieke 
vragenlijst, waarbij de FACT (Functional Assessment of Cancer Therapy) 
vragenlijst meestal werd aangegeven. Van de respondenten wilde 60% graag de 
vragenlijst in de klinische setting invullen omdat het hen zou helpen hun problemen 
aan hum specialisten duidelijk te maken. Daarentegen wilde 40% van de patiënten 
de vragenlijsten niet gebruiken omdat ze het gevoel hadden dat deze niet relevant 
voor hun toestand waren en het invullen teveel tijd in beslag nam. 
 
 
Conclusies 
 
 Kwaliteit van leven is een subjectief fenomeen, door de patiënt zelf 
gerapporteerd, dat aan verandering in de tijd onderhevig is. 
 
 Kwaliteit van leven is een integraal onderdeel van de evaluatie van de 
behandelingsresultaten bij hoofd-halskanker. 
 
 Kwaliteit van leven neemt gewoonlijk af direct na de behandeling; neemt daarna 
geleidelijk weer toe tot het niveau van voor de behandeling, doorgaans in een 
tijdsbestek van 12-18 maanden. 
 
 Een significante daling kwaliteit van leven op lange termijn wordt waargenomen 
10 jaar na het stellen van de diagnose. De kwaliteit van leven van voor de 
behandeling blijkt een voorspeller van deze niveaudaling. Geen enkele van de 
demografische factoren en ziekte - of behandeling gerelateerde factoren kon 
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kwaliteit van leven op lange termijn in de univariate analyses voorspellen, maar 
dat berustte mogelijk op een te kleine steekproefomvang. 
 
 De kwaliteit van leven na de behandeling blijkt een krachtige, significante 
voorspeller van lange termijn overleving bij hoofd-halskanker. Enkele 
persoonlijkheidskenmerken gemeten voor de behandeling en een aantal andere 
psychosociale factoren na de behandeling gemeten (b.v. pijn in het hoofd-
halsgebied, de score van eten, spreken en SF-36 lichamelijk functioneren) 
blijken significant geassocieerd te zijn met lange termijn overleving. 
 
 De meeste hoofd-halskanker specialisten evalueren niet routinematig de 
kwaliteit van leven door middel van een vragenlijst omdat zij menen dat het te 
veel tijd in beslag neemt en geen bewezen bijdrage levert aan het klinisch 
beleid. 
 
 Patiënten geven aan dat kwaliteit van leven vragenlijsten bij hoofd-halskanker 
effectief hun gezondheidsaspecten weergeven. De meesten geven er de 
voorkeur aan deze vragenlijsten in het ziekenhuis in te vullen als ondersteuning 
bij het meedelen van hun klachten aan de arts bij het polikliniekbezoek.  
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 Summary of clinical and academic experience 
 
Hisham Mehanna took up post as a full-time Consultant Otorhinolaryngologist and 
Head and Neck surgeon at University Hospitals Coventry and Warwickshire in 
2004. His subspecialties are head and neck and thyroid surgery. He is also an 
honorary associate clinical professor at Warwick Medical School. Hisham Mehanna 
is the Clinical Lead for Head and Neck Cancer at University Hospitals Coventry. He 
is also the Chair of the Joint Arden Head and Neck Cancer Centre.  
 
Hisham holds over £3m in research grants. He is the chief investigator of PET 
NECK, a multicentre RCT examining the role of PET CT in the management of 
advanced head and neck cancer. He led a multi-institution consortium to secure a 
large grant from the Health Technology Assessment Unit, and has set-up the trial 
in 24 head and neck centres around the UK. Mr Mehanna is also the chief 
investigator of PET NECK Collect, which is a tissue bank that is funded by Cancer 
Research UK. He is also the chief investigator of a Macmillan Cancer-funded 
project examining a new concept in delivery of head and neck cancer care in the 
clinic. He is second investigator in a Cancer Research–UK LiNHCS trial. He has 
also attracted contract research work from several large multinational 
pharmaceutical companies. 
 
 
Hisham supervises several PhD, MD and MSc students. He also runs an annual 
international postgraduate ‘Masters’ courses in head and neck surgery (since 
2004). He has also organised several national meetings including those for the 
Otorhinolaryngological Research Society and the British Association of 
Otorhinolaryngologists-Head Neck surgeons. He has been a faculty member on 
several national and international courses. He is also the Higher Surgical Training 
Representative for Otorhinololaryngology-Head and Neck surgery at University 
Hospital Coventry.  
 
In addition, he is a member of the National Clinical Research Institute head & neck 
clinical studies group that reviews funding applications for clinical trials and makes 
recommendations to research charities. He is also chair of its surgery & localised 
therapies sub-group. He also sits on the Interventional Technologies advisory 
panel of the Health Technology Assessment Unit. He is also Honorary Secretary of 
the Otorhinolaryngological Research Society, and Chair of the Research 
Committee of the British association of Head and Neck Oncologists. 
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